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Abstract 
 Metabolic syndrome (MetS) is a growing problem around the globe. According to most 
definitions, this syndrome is characterized by the concurrent manifestation of 3 or more of the 
following five factors: enlarged waist circumference (WC), elevated triglycerides (TG), low high-
density lipoprotein cholesterol (HDL), high blood pressure and impaired glucose tolerance. 
Diagnostic criteria for this syndrome have been defined by several entities and the definition has 
changed with time (1). One criterion that remains a subject of debate is WC. Measuring WC is a 
non-invasive technique to assess abdominal obesity. Ethnicity dependent cutoffs for WC have been 
established, however those designated for the Mexican population have been shown to be 
inadequate for accurately assessing risk for disease because they are based on a South Asian 
population (2, 3).  
 MetS and obesity itself are the product of a complex interplay between environment, 
lifestyle, diet and genetics. These factors can interact with each other, making developing 
interventions and determining causal relationships difficult. Investigations into the interactions 
between diet and our genetic code have wielded promising data suggesting that changing the diet 
can affect how our genes are expressed (4). Research is targeting specific nutrients both on the 
macro and micro scales. Vitamin A and carotenoids are one such target.  
 Retinoids are key in facilitating many physiological functions from cell differentiation and 
embryogenesis to vision and lipid metabolism (5). Vitamin A and carotenoids are compounds that 
demonstrate the activity of retinoids and have shown importance in determining health outcomes 
related to obesity and dyslipidemia. The availability of retinoids for body processes is somewhat 
dependent on the activity of β, β-carotene-15,15-oxyegenase 1 (BCO1). However, studies show 
that humans exhibit both low and high conversion rates of provitamin A carotenoids to functional 
 
 
iii 
 
retinoids. This may be due to single nucleotide polymorphism (SNPs) within and upstream of the 
BCO1 locus impart changes in the efficiency of conversion of β-carotene to retinol (6, 7). Given 
the connection between carotenoid derivatives and lipid metabolism it is interesting that the 
association between the genotype of BCO1 and the lipid profile has been poorly examined in 
humans.  
The work presented here is based on research from the Universities of San Luis Potosi and 
Illinois: A Multidisciplinary Investigation on Obesity, Genetics and Socio-environment (UP 
AMIGOS) project. A large cohort of college applicants to the University of San Luis Potosi 
participated in this cross-sectional study. Biological, anthropometric, dietary, physical activity, 
and psychological data was collected from close to 10,000 individuals. The objectives of this 
research are as follows: 1) Examine the prevalence of MetS in a cohort of young Mexican adults 
based on three sets of diagnostic criteria in order to determine if a proposed set of WC cutoffs 
correlate more positively with components of metabolic syndrome, 2) Investigate the association 
between BCMO1 SNPs and serum lipid levels in college-age individuals from the UP AMIGOS 
cohort and further, to ascertain whether dietary intake of carotenoids has an effect on these 
relationships, and 3) Conduct a pilot study, implementing a protocol developed for the collection 
and measurement of serum carotenoids in addition to dietary intake. 
The overall hypothesis of this work is that a cohort of young Mexican adults will show 
evidence of risk for factors of MetS. The lipid profile in this population will be associated with 
genetic variation in the BCO1 locus. Dietary intake of these individuals will be a mediating factor 
in this relationship.  
The first study presented here examines the prevalence of MetS in a subset of participants 
from the UP AMIGOS project (n=668) aged 18 to 25 years. These individuals provided 
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anthropometric and biological data as well as blood for measurement of serum lipids. MetS and 
components thereof were diagnosed according to the criteria used International Diabetes 
Federation (IDF), American Heart Association (AHA) and a proposed set based on a sample of 
Mexicans (MEX). The only difference among these three are the WC cutoffs which were defined 
for men and women as follows: 90 and 80 cm by IDF, 102 cm and 88 cm by AHA and 98 cm and 
84 cm by MEX. The prevalence of MetS in this cohort of young Mexican adults was less than 15% 
across all definitions. Correlations between WC and body mass index (BMI) and other components 
of MetS (TG, HDL, blood pressure, and elevated fasting blood glucose) were examined. The MEX 
WC cutoffs were found to be more highly positively correlated with diastolic blood pressure and 
negatively correlated with HDL in females than the other sets of WC cutoffs. Additionally, average 
TG and diastolic blood pressure was higher in males that had elevated WC according to the MEX 
criteria than those identified by the IDF and AHA cutoffs. Our study shows that the current WC 
cutoff criteria used to assess risk may not be adequate for identifying individuals who are truly at 
risk. WC criteria that are specific and sensitive enough to detect those in the Mexican population 
who are truly at risk will help public health entities allocate scarce resources more effectively. 
In the second study, 767 individuals, aged 18 to 25 years, who had the most complete data 
and provided blood and serum for analysis were included. DNA was extracted from whole blood 
and genotypes for five SNPs within and upstream of the BCO1 gene locus were determined. Also, 
511 of these participants took the time to adequately fill out a food frequency questionnaire for 
assessment of dietary intake. Significant associations were found between the minor alleles of 
BCO1 SNPs rs6564851 and rs6420424 and increased total cholesterol (TC), low-density 
lipoprotein (LDL) and non-high-density lipoprotein (non-HDL) levels. These associations were 
not only maintained, but became stronger in a subset of this sample (n=511) when we accounted 
 
 
v 
 
for dietary fat and carotenoid intake. Our analyses for objective two reveal that SNPs in BCMO1 
were associated with plasma lipid levels and that is relationship is mediated by dietary intake. 
Knowing the risk for abnormal lipid levels is increased depending on genotype for this enzyme 
could be a target of potential interventions in the future that address both dietary and genetic 
interactions. 
In addition, we recruited a small pilot cohort (n=20) to assess the feasibility of collecting 
blood and serum samples for the measurement of carotenoids in this population. The 
implementation of the pilot study was successful. Our study sample showed few differences from 
the larger UP AMIGOS cohort which indicated that this protocol can be successfully replicated in 
the larger cohort. Positive correlations were observed between the measured intake of retinol and 
lycopene with estimated intakes of α-carotene, lycopene and its isoforms. Also, circulating levels 
of carotenoids were significantly correlated with the lipid profile of study participants. The 
successful execution of this unique data collection protocol has proven feasible with the available 
staff and facilities available to our collaborators. The relationships between intake and plasma 
levels of carotenoids show that assessment of intake of these nutrients is possible using a FFQ and 
that this could aid in the development of a tool that can be used to assess carotenoid status and, 
subsequently, health in this population.  
Looking toward the future we would expand our analysis to produce WC cutoffs for this 
specific population. Examining the correlation of a specific set of WC criteria with components of 
MetS would allow us to validate these cutoffs as accurate assessment criteria.  As the longitudinal 
arm of the UP AMIGOS project continues we hope to investigate the details of the relationship 
between genotype of BCO1 and the lipid profile. Future intervention studies would be aimed at 
examining the effect of carotenoid administration on the lipid profile based on low and high 
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converter genotypes. Overall, this work will contribute to the improvement of our ability to assess 
risk for metabolic disease in this population. 
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Chapter 1 
Introduction 
 
Metabolic Syndrome is a Public Health Problem 
In the United States (U.S.), 69.0% of adults aged 20 years or older are overweight or obese 
while 18.4% of adolescents (12-19 years old) are obese (1). Obesity is just one facet of the larger 
problem of metabolic syndrome (MetS). The risk factors for MetS are also rampant in the U.S. 
population, where 53% of adults have abdominal obesity (AO), 40% have hypertension and 39% 
have hyperglycemia (2). Additionally, the distribution of MetS risk is not homogenous across all 
ethnicities. Latinos are the fastest growing minority population in the United States and show 
greater occurrence of overweight and obesity than other minority groups. According to the results 
of the 2012 National Health and Nutrition Examination Survey (NHANES) 77.2% of Hispanic 
women and 78.6% of Hispanic men are obese, while 69.1% of non-Hispanic black and 42.4% 
males and 82.1% non-Hispanic females,  are overweight or obese (1).  
Mexico has surpassed the U.S. in prevalence of overweight and obesity with 71.3% of 
adults being overweight or obese (3). Additionally, Mexico is showing a startling growth in 
prevalence of MetS according to the 2006 Mexican National Health and Nutrition Survey, 49.8% 
of adults had three or more of the criteria for metabolic syndrome, 74.2% of which showed 
increased WC according to the International Diabetes Federation cut offs (3). Also, the Study on 
global AGEing and adult health (SAGE), found that adult Mexicans presented with the highest 
prevalence of elevated waist-to-hip ratio compared to those in China, Ghana, India, Russia and 
South Africa (4).  
Young adults are a commonly overlooked population when it comes to public health 
initiatives for health screening and disease prevention. Risk for non-communicable disease is 
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found in children younger than 10 years. A recent study that examined children in northern Mexico 
found that half of a cohort of 450 children had at least one plasma lipid measurement that was 
abnormal. Furthermore, these researchers found that 2.9% of these children showed abnormalities 
in all five lipid categories including total cholesterol (TC), high-density lipoprotein (HDL), low-
density lipoprotein (LDL), non-high-density lipoprotein (non-HDL) and triglycerides (TG), with 
elevated TG being the most prevalent (63.0%) (5). These problems seem to persist through 
adolescence as it has been shown that the young adult and adolescent Mexican population is at 
even greater risk than their U.S counterparts at developing cardiovascular disease (CVD) at 
younger ages (6).  
Public health initiatives to improve the health of the Mexican population have focused on 
reaching the community. A randomized controlled intervention study examined the efficacy of 
community health workers on increasing compliance with preventative care measures (7). This 
study found that the “promotoras” or community health workers were effective at encouraging 
Mexican women to stay current with their health screenings and check-ups (7). However, few 
intervention studies have been published that have addressed the adolescent and college-age group 
in Mexico.  
Development of Dyslipidemia: The Roles of Environment and Genetics  
 Plasma lipid levels are determined by a combination of factors. Dietary intake of fat, 
specifically saturated and trans fatty acids, have long been implicated as the main contributors to 
plasma cholesterol levels (8). This complicated relationship is further affected by exercise and 
hormone levels (9, 10). The physiological mechanism for lipid metabolism is equally complex. 
Dietary intake of foods begins the exogenous pathway for lipid metabolism. By-products of 
digestion, specifically of dietary fat, are absorbed into the body from the intestine and incorporated 
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into chylomicrons. These bodies then deliver triglycerides to body tissues or are carried to the liver 
where they contribute to the production of VLDL in the liver (11). The endogenous pathway of 
plasma lipid production involves the action of the liver. The liver is also capable of producing lipid 
particles from non-lipid precursor molecules. Lipid metabolism in the liver involves transport of 
TG to peripheral tissues by way of VLDL. Once in circulation VLDL is quickly converted to IDL 
and subsequently LDL. Reverse cholesterol transport, the process of bringing cholesterol from 
body tissues back to the liver, involves HDL, which takes TG from body tissues back to the liver 
for recycling or elimination (11).   
 More than 100 genetic loci have been identified that contribute to plasma lipid 
concentrations (12). Of particular interest are peroxisome proliferator-activated receptors (PPAR) 
which are a prominent players in lipid levels related to obesity and the inflammatory consequences 
thereof. These transcription factors function as regulators of lipid metabolism and have been found 
to respond to a variety of stimuli in the diet including dietary fats as well as micronutrients (13). 
Their mechanism of action involves forming heterodimers with retinoid X receptors (RXR) in 
response to substrates derived and composed of lipids (14). PPARγ, in particular, is expressed in 
adipose tissue and so is closely tied to the differentiation and function of adipocytes. This protein 
regulates lipid storage, adipocyte differentiation as well as insulin sensitivity (14). For PPARγ to 
be effective at regulating these important, anti-obesogenic processes its ligand RXR must be 
activated by retinoic acid. For this reason, retinoic acid has been shown to be a co-regulator of 
lipid metabolism (15). Retinoic acid is obtained from dietary vitamin A and provitamin A (ProA) 
compounds.  
 
 
 
 
4 
 
Central Hypothesis and Study Aims 
 The deleterious effects of obesity are widespread and serious in nature. It is the increasing 
number of deaths associated with the comorbidities of unhealthy accumulation of body fat that has 
sparked a slew of research aimed at identifying the causes and avenues for intervention to prevent 
more lives from being adversely effected by this disease. It is the intention of this work to 
contribute to the body of knowledge that will contribute to developing interventions that address 
the genetic and dietary components of obesity.  
The central hypothesis guiding this research was that cohort of young Mexican adults will 
show evidence of risk for factors of MetS and the lipid profile in this population will be associated 
with individual genetic variation in the BCO1 locus. The dietary intake of these individuals will 
be a mediating factor in this relationship. To test this hypothesis, the aims of this research were: 
1) To assess the prevalence of MetS and components thereof in a cohort of young Mexican adults 
in order to evaluate the predictive value of different WC cutoffs for risk of metabolic disease, 2) 
To describe the associations between SNPs within the BCO1 gene locus and facets of the lipid 
profile in young Mexican adults, and 3) Explore the way dietary intake of carotenoids mediates 
the relationship between SNPS in BCO1 and the lipid profile in young Mexican adults. 
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Chapter 2 
Literature Review 
 
This literature review will provide background and justification to investigate a) the 
prevalence of metabolic syndrome (MetS) and components thereof in a sample of young Mexican 
adults based on established and Mexican-specific criteria for waist circumference, b) the 
hypothesis that there is an association between single nucleotide polymorphisms within the β-
Carotene 15-15’-oxygenase (BCO1) gene locus and the lipid profiles of young Mexican adults and 
c) that this relationship is mediated by dietary intake of carotenoids. A description of the 
functionality and regulation of this enzyme are provided here. In addition, the actions of Vitamin 
A and its derivatives as they pertain to lipid metabolism are described.  
Metabolic Syndrome 
Metabolic Syndrome is a grouping of factors that are associated with increased risk for 
metabolic disease and stem from obesity, lack of exercise and poor diet (1). The definition as it is 
known today, was conceptualized by Reaven in his 1988 Banting Lecture and was classified as 
Syndrome X. This model of MetS was focused around insulin resistance and the link to CVD risk 
(2). Epidemiological studies have shown that MetS is linked to CVD risk as well as four of the 
other ten top causes of death in the world including hypertensive heart disease, diabetes mellitus, 
stroke, and chronic obstructive pulmonary disease (COPD) (3). According to current definitions, 
MetS is characterized by the concurrent manifestation of three or more of five factors that 
individually predict CVD and other metabolic disease risk. However, the International Diabetes 
Federation, stipulates that the diagnosis of MetS depends on the presence of enlarged waist 
circumference (WC) coupled with two or more of the following: elevated TG, low HDL, elevated 
blood pressure (BP) and insulin resistance (IR) (4). The practical implication of defining MetS 
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using these criteria relates to their predictive value regarding risk for CVD and type II diabetes 
mellitus (T2DM). Individual diagnoses of dyslipidemia, hypertension, insulin resistance and 
central adiposity have been strongly associated with a substantial increase in risk for CVD and 
T2DM (5). Together these conditions exacerbate these risks by as much as 2- to 3-fold (5-7). The 
World Health Organization, International Diabetes Federation and the American Heart have 
separately published the most widely used sets of criteria for the diagnosis of MetS. Although there 
are some differences, the basic components are the same and are summarized in Table 1. Having 
several definitions is well justified, but confusing, as there are separate definitions for different 
ethnic and age groups (5).  
Elevated Waist Circumference 
Early in the development of the concept of MetS, it was recognized that obesity 
significantly contributes to the development of metabolic disease and so is a key facet in defining 
MetS (8). This relationship was further characterized by implicating a specific type of obesity, 
abdominal or central obesity, as the stronger contributor to CVD and T2DM (9). In the clinical 
setting, obesity is assessed using BMI, a ratio of weight (kilograms) and height (square meters), 
where a BMI of 30 kg/m2 or greater categorizes and individual as obese. BMI, as an anthropometric 
measure, is meant to assess degree of body fatness but does not take into account the ratio of lean 
to fat mass nor the distribution of body fat (8). This distinction is important, as it is the percent of 
fat mass in the body and its distribution that contribute to disease.  
A recent review by Karpe and Pinnick regarding the biological implications of abdominal 
versus lower body obesity, found that abdominal obesity is of greater metabolic importance than 
lower body fat (10). Differences in body fat distribution are the basis of the metabolically healthy 
versus the metabolically unhealthy obese conditions. There is mounting evidence that lower body 
 
 
8 
 
fat accumulation was beneficial for lipid metabolism while the visceral or abdominal adipose tissue 
favored fat storage and hindered the removal of very low-density lipoprotein (VLDL) (11). 
Adipose tissue has been shown to possess endocrine properties that are associated with increased 
inflammation (12). The inflammatory processes that are increased with elevated body fatness are 
shown to increase risk for disease (13). These inflammatory processes have been found to not only 
increase obesity but also contribute to other complications of obesity, including insulin resistance 
(14). Thus, more specific measures of adiposity are necessary to assess the true amount and 
distribution of adipose tissue in the body, specifically in the abdominal region.  
Hypertriglyceridemia 
 Serum triglycerides are measured as an indicator of the amount of fat, endogenous or 
exogenous in the blood stream (15). Having a triglyceride level of greater than 150 mg/dL (1.7 
mmol/L) is considered elevated for adults over 20 years of age (4). Triglycerides are found in the 
greatest abundance in chylomicrons from the small intestine and VLDL that is synthesized in the 
liver (16). The production of triglyceride rich lipoproteins is governed by both environmental and 
genetic factors and can be mediated by the presence of obesity and insulin resistance (17, 18). 
Triglycerides, as a biomarker for disease risk, have been shown to be indicative of the potential 
for atherogenesis in the body (19). Therefore hypertriglyceridemia is included in the diagnosis of 
MetS due to its link to metabolic dysfunction, specifically insulin resistance and atherogenic heart 
disease.  
Low High Density Lipoprotein 
 HDL cholesterol is responsible for the transport of cholesterol from body tissues and 
macrophages to the liver where it is recycled or disposed of (16). Having adequate amounts of 
circulating HDL, greater than 40 mg/dL in men and greater than 50 mg/dL in women, is thought 
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to indicate increased capacity for reverse cholesterol transport, thereby reducing risk for 
atherosclerosis and other CV consequences, especially in women (20, 21). HDL levels, unlike the 
other constituents of the lipid profile (total cholesterol [TC], low-density lipoprotein [LDL] 
cholesterol and TG) are not as easily influenced by diet and are more receptive to change in 
response to genetic and other factors (22). A recent review by Brewer et al., found that ATP-
Binding Cassette Transporter (ABCA1) gene expression is positively linked to HDL levels in the 
plasma (23). Tofighi et al. demonstrated that aerobic exercise increased expression of ABCA1 
over 12 weeks of training and, subsequently, HDL also increased (21). One recent study examined 
the effect of omega-3 fatty acids and plant sterols on the subclasses of the lipid profile and showed 
that supplementation with these compounds can affect the size and composition of HDL particles 
(24). Efforts focused on implementing interventions that might increase HDL levels are important 
as this lipoprotein is known to confer significant influence on cardiovascular health outcomes (20).  
Increased Blood Pressure 
 Increased blood pressure, or hypertension, in MetS is defined as having a systolic blood 
pressure (DBP) >130 mmHg and/or a diastolic blood pressure >85 mmHg (4, 10, 25). Pre-
hypertension (HTN) has been established as a principle contributor to the development of CVD. 
Adverse health effects of elevated blood pressure include cardiomyohypertrophy; vascular 
damage; increased risk of stroke, myocardial infarction and kidney disease (26). With ischemic 
and hypertensive heart disease listed as two of the top ten causes of death in the world, control of 
HTN is an prominent public health issue. Genetic and lifestyle factors contribute to the 
development of HTN. Primary intervention addresses factors such as diet and sedentary behavior. 
The medications prescribed for treatment of HTN include pharmacological agents that function in 
a variety of mechanisms including water balance and physiological function of the heart.  
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Insulin Resistance  
 IR, also referred to as impaired glucose tolerance, is commonly indicated by a fasting blood 
glucose (GLC) level of greater than 100 mg/dL (27). This condition is indicative of dysfunction 
of the body’s ability to process glucose due to inability of body cells to respond to insulin (28). 
Elevated blood glucose is detrimental to health for a variety of reasons. Elevated blood glucose 
causes widespread damage to the small blood vessels throughout the body. This is also a hallmark 
characteristic in uncontrolled T2DM. Consequences of uncontrolled T2DM include kidney 
dysfunction, nerve damage and is the leading cause of adult blindness and is linked to increased 
risk for several types of cancer (29, 30). Uncontrolled T2DM is also the primary cause of non-
traumatic limb amputation and disables millions of people around the world each year (31). 
Primary treatment for IR most commonly revolves around a carbohydrate-controlled and often 
calorie restricted diet. Studies have also shown that exercise improves insulin sensitivity by 
increasing the number of insulin receptors and decreasing weight (28). Medical intervention for 
IR includes a variety of medications as well as delivery of exogenous insulin via injection when 
the pancreas can no longer produce insulin.  
Vitamin A and Carotenoids 
Description, Sources and Metabolism  
 Vitamin A is a fat soluble micronutrient that is actually a term used for a group of 
compounds that possess the active characteristics of all-trans retinol. Vitamin A is derived from 
dietary sources either as all-trans retinol, preformed vitamin A, or ProA carotenoids (those 
carotenoids with the potential to be converted to vitamin A) (32). Preformed vitamin A is most 
commonly found in animal-derived foods such as dairy products, organ meats, eggs and fish, 
among others (33). Additionally many foods are now vitamin A fortified including most cereals 
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and other grains. ProA carotenoids, however, are abundant in plants. There are over 600 known 
compounds that are considered carotenoids but only 60 of those have been found to have vitamin 
A characteristics (32). These compounds make up the yellow, orange and red pigments seen in 
plants. The ProA carotenoids that are common in the human diet include β-carotene, α-carotene 
and β-cryptoxanthin. These compounds are found in fruits and vegetables including carrot, papaya, 
sweet potato, pumpkin and tomato. However, β-carotene in particular has the greatest ProA 
activity, once absorbed and processed it can produce two complete molecules of all-trans retinol 
(32).  
 Carotenoids vary in bioavailability depending on the source and the content of the meal. 
Most often, once chemical digestion of proteins occurs in the stomach, vitamin A and other ProA 
compounds become associated with the lipid portion of the meal. Absorption is improved with the 
addition of fat to the meal as these compounds are soluble in fat. Once freed from the food matter, 
carotenoids and vitamin A are digested along with the triacylglycerides, phospholipids and 
cholesterol esters in the small intestine. Absorption of ProA carotenoids has been proposed as both 
a facilitated and passive process, however a study that examined the uptake of various carotenoids 
and retinol by human Caco-2 and HEK cells found that two receptors influenced the uptake of 
carotenoids. Cells transfected with scavenger receptor class B type I (SR-BI) and cluster 
determinant 36 (CD36) demonstrated a one to two-fold increase in uptake of ProA carotenoids but 
not retinol (34). Vitamin A and carotenoids are processed post absorption as described in 
subsequent sections. Once processed these molecules are incorporated in and absorbed as micelles 
into the lymphatic system.  
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Actions of Vitamin A and derivatives in lipid metabolism 
 Once absorbed in the proximal small intestine, vitamin A and its derivatives are distributed 
to body tissues. Chylomicrons absorbed into the lymphatic system are carried to circulation and 
deliver retinyl esters, unesterified retinol and carotenoids to body tissues. The remaining retinoids 
are delivered to and stored in the liver where these compounds can be converted to retinol and 
released to retinol binding protein 4 (RBP4). Transport of vitamin A and derivatives through the 
plasma is carried out by RBP4 (35). RBP4 is the primary transporter of vitamin A and carotenoids 
in the blood, however retinyl esters can also be transported by chylomicrons. Once in circulation, 
receptors are required for retinoids to be taken up into cells. Stimulated by retinoic acid 6 (STRA6) 
is the receptor found to be responsible for cellular uptake of retinol from RBP4. This receptor is 
found on many tissues throughout the body including the placenta, testis and nervous tissue (36). 
The effects of retinoids and retinoic acid are varied and widespread. Retinoic acid plays a role in 
cell differentiation, embryogenesis, adipogenesis and hepatic lipid metabolism (37). As described 
previously, retinoic acid’s role in these processes is in part mediated by PPARγ and RARs.  
Conversion of Provitamin A Carotenoids 
Enzymes are responsible for conversion of dietary carotenoids 
 In addition to their antioxidant and anticarcinogenic activity, dietary carotenoids provide 
precursors for vitamin A and retinoic acid which participate in other body processes. The most 
prevalent ProA carotenoids found in human tissues include β-carotene, α-carotene and β-
cryptoxanthin (38). The by-products of cleavage of these compounds can be converted to the 
biologically active molecules, all-trans-retinoic acid and 11-cis-retinal (39). The enzymes 
responsible for initial cleavage of these substances are β-carotene-15, 15’-oxygenase 1 (BCO1) 
and β-carotene-9’,10’- oxygenase 2 (BCO2) (40). These enzymes are expressed in several body 
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tissues including intestinal enterocytes, liver and lung epithelium (41, 42). Several studies in mice 
have shown that BCO1 is expressed in intestinal enterocytes as well as hepatocytes (43). BCO1 
and BCO2 vary in their specificity of substrates with BCO1 demonstrating more stringent cleavage 
targets. BCO2 has a broad range of carotenoid substrates including xanthophylls which do not 
have vitamin A activity but may participate in signaling pathways throughout the body (44). A 
study by dela Sena and collaborators, demonstrated that human recombinant BCO1 strongly favors 
β-apocarotenals and carotenoids with more than 22 carbons. Utilizing α-tocopherol during 
incubation minimized oxidation of β-carotene to obtain unadulterated reaction rates, BCO1 
showed activity with β-carotene, lycopene, α-carotene, and β-cryptoxanthin but not with 
zeaxanthin and lutein (45). Conversely, BCO2 shows affinity for a broad range of substrates and 
will cleave both carotenoids and xanthophylls (37). BCO1, however, is closely linked to plasma 
levels of carotenoids and has been identified as the principle converter of BC to vitamin A (38). 
The exact mechanism of BCO1’s effect on the bioavailability of xanthophylls remains to be fully 
characterized but is thought to involve vitamin A (41).  
Regulation of BCO1and carotenoid metabolism 
The regulation of expression of BCO1 is controlled by a negative feedback loop that 
consequently controls the production of vitamin A. Studies have identified several mechanisms 
for control of BCO1 expression in different tissue types. The common thread in these mechanisms 
is the extensive presence of regulatory binding sites within the promotor region of the BCO1 gene 
locus. (41, 42, 46). The process of conversion of BC to its vitamin A derivatives begins with 
absorption. SR-B1 facilitates absorption of BC and other ProA carotenoids in the small intestine 
(41). Dietary fats improve bioavailability of BC and other fat soluble micronutrients. A study in 
rats characterized the fatty acid composition of the diet and its effect on the conversion of BC (47). 
 
 
14 
 
Hosotani et al. found that n-3 polyunsaturated fatty acids and monounsaturated fatty acids enhance 
the action of BCO1 in the intestine while saturated fatty acids were found to decrease BCO1 
activity in hepatic cells (47). A review by Lietz et al. summarizes the involvement of fatty acids in 
regulation of BCO1 as a co-repressor bound to PPARγ which, in conjunction with RXRα, binds to 
PPAR response elements upstream of the BCO1 gene to induce expression of the enzyme (48).  
The negative feedback regulation of BCO1 involves a derivative of vitamin A produced by 
cleavage of ProA carotenoids. As demonstrated by Lobo et al., retinoic acid (RA), once produced, 
serves as a ligand for retinoic acid receptors (RAR) which form heterodimers with RXRs. This 
begins signaling cascades for several processes, such as PPARγ control of lipid metabolism. In the 
case of BCO1 regulation, when RA is low, the RAR-RXR heterodimer binds retains a co-repressor 
that allows it to bind to retinoic acid response elements (RAREs) in the promotor region of the 
intestine-specific homeobox (ISX) gene locus. This represses the expression of this inhibitory 
transcription factor which then allows for an increase of expression of BCO1. With an increase in 
BCO1 expression, more RA is produced. RA in turn, replaces the co-repressor on the RAR and 
allows for ISX transcription. ISX binds to regulatory sites in the promotor region of BCO1 that 
inhibit its expression. Increase in ISX also inhibits the expression of SR-B1 which decreases the 
absorption of BC from the intestinal lumen (48). The regulation of BCO1 and the accessory factors 
that contribute to carotenoid absorption and cleavage are shown in Figure 1.  
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Figure 1: Absorption of carotenoids and regulation of conversion of BC to Retinal 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1A: Model of mechanism for absorption of carotenoids from lumen of the small intestine by SR-B1. Fig. 1B: 
Regulation of transcription of SR-B1 and BCO1 by ISX in retinoic acid abundant and scarce environments. 
Abbreviations: SR-B1: Scavenger receptor class B type 1; BCO1: β-carotene oxygenase 1; RXR: Retinoid X receptor; 
RAR: Retinoic acid receptor; CA: Co-activator; RA: Retinoic acid; CA: Co-activator; CR: Co-repressor; RARE: 
RAR-RXR Response element; ISX: Intestine specific homeobox. Adapted from (41, 48). 
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Genetic variation in the BCO1 gene locus affects conversion efficiency 
 Genome-wide association studies (GWAS) are utilized to identify single nucleotide 
polymorphisms (SNPs) associated with various phenotypes. A GWAS conducted by Ferrucci and 
colleagues identified several SNPs linked to differences of circulating carotenoid levels in samples 
of Italians, women from the Women’s Health and Aging Study and the α-tocopherol, BC Cancer 
Prevention Study. The combined results of these studies identified four SNPs that mapped to the 
region of chromosome 16 just upstream of the BCO1 gene locus. These SNPs included rs6420424, 
rs6513787, rs11645428 and rs6564851 (49). The effect of two of those SNPs in addition to two 
others, rs7501331 and rs12934922 within the coding region of BCO1, were characterized in a 
small sample of females volunteers. This study, conducted by Lietz et al., found that the SNPs 
rs12934922, rs7501331, rs6420424, rs11645428 and rs6564851 were associated with a significant 
reduction in the catalytic action of BCO1 by over 48% (50). Furthermore, one study conducted by 
Hendrickson et al. examined the relationship between SNPs within BCO1 gene locus with plasma 
carotenoid concentrations in women of European descent. These researchers found that the G-
allele of rs6564851 and T-allele of rs12934922 were associated with higher serum levels of BC, 
AC, BCr and lutein/ zeaxanthin but no associations were found with lycopene or retinol. 
Additionally, the T-allele of rs7501331 was associated with lower serum BC and AC (51). To 
bring to light the practical implications of conversion efficiency of this enzyme, a study by Leung 
et al. examined two SNPs within the coding region of BCO1 for a link to plasma levels of 
carotenoids in humans (52). The diet of 28 female volunteers was monitored closely for four days 
and daily nutrient intakes were calculated and plasma concentrations of carotenoids were measured 
by HPLC analysis. This study demonstrated that two SNPs within the BCO1 gene locus can 
account for the low converter phenotype of BCO1. The variant alleles of rs7501331 and 
 
 
17 
 
rs12934922, in combination, showed 69% lower activity of BCO1 in these volunteers which was 
correlated to a significantly higher concentration of BC in the plasma (52). Altogether, these 
studies define the genetic variation present within and upstream of this locus. The implications of 
the low converter phenotype, defined as those that show decreased catalytic activity of BCO1, are 
that the availability of derivatives of carotenoids, especially retinoic acid, is diminished. The 
limited availability of RA, in turn may affect other body processes that depend on retinoic acid.  
Translation of dietary intake of carotenoids to plasma levels  
The studies mentioned above have characterized individuals as either high or low converters 
of BC. The efficiency of BC conversion demonstrates a dependence on several genes and is 
influenced by many SNPs within and around those loci (48). For this reason, the translation of 
dietary intake of carotenoids to circulating plasma levels of these molecules is subject to influences 
that can obscure the relationship between the two measures (53, 54). Nutritional epidemiological 
studies attempt to measure dietary intake in an effort to understand the relationship between intake 
and disease (55). Food frequency questionnaires developed specifically for particular disease states 
or for assessing individual nutrients are common tools used to inform researchers. A study 
conducted by Romieu et al., sought to evaluate the ability of a specialized food frequency 
questionnaire to capture dietary intake of carotenoids (56). This group found that the estimated 
intake of carotenoids correlated well with serum levels of BC, lutein, zeaxanthin and retinol (56). 
Assessment tools that can be applied on a large scale are important for designing public health 
initiatives aimed at assessing and improving the health of large populations.  
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Table 1: Definitions of Metabolic syndrome across entities and time  
 
World Health 
Organization 
1999 European 
Group for the 
Study of Insulin 
Resistance 
(EGIR) 
National 
Cholesterol 
Education 
Program 
(NCEP) 
2003 American 
Association of 
Clinical 
Endocrinologists 
(AACE)  
2005 
International 
Diabetes 
Federation (IDF) 
2005 American 
Heart 
Association and 
National Heart, 
Lung and Blood 
Institute 
(AHA/NHLBI) 
2009 Current 
Harmonized 
Definition  
Impaired glucose 
tolerance (IGT) 
Impaired glucose 
tolerance (IGT) 
Any 3 of the 
following: 
Glucose 
intolerance to 
some degree (but 
not overt 
diabetes) 
Central obesity 
(BMI > 30 kg/m2 
or if ≤ 30 kg/m2 
by ethnic specific 
WC 
measurements) 
Any 3 of the 
following: 
Any 3 of the 
following: 
Impaired fasting 
glucose (IFG) or 
diabetes mellitus 
and/or insulin 
resistance 
Impaired fasting 
glucose (IFG) 
Obesity  
(WC ≥ 102 cm 
(40 inches) in M 
and ≥ 88cm (35 
inches) in F) 
Abnormal uric 
acid metabolism 
The above along 
with two of the 
following: 
Elevated WC   
(M: ≥ 102 cm (40 
inches) and         
F: ≥ 88 cm (35 
inches)) 
Enlarged WC 
The above with 
two or more of 
the following: 
The above with 
two or more of 
the following: 
Hypertension (BP 
≥ 130/85 mm Hg) 
Dyslipidemia TG ≥ 150 mg/dL TG ≥ 150 mg/dL 
and HDL-c < 40 
mg/dL in M and < 
50 mg/dL in F 
Elevated TG (≥ 
150 mg/dL) 
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Table 1 Continued. 
 
Hypertension 
(BP≥160/90 mm 
Hg) 
Raised plasma TG 
(≥150 mg/dl) 
and/or low HDL-
cholesterol (<35 
mg/dl for M and 
<39 mg/dl for F) 
GLC > 110 
mg/dL 
Hemodynamic 
changes 
(including 
hypertension) 
HDL-c < 40 
mg/dL in M or 
<50 mg/dL in F 
Elevated blood 
pressure ≥ 130/85 
mm Hg 
Decreased HDL-c 
(< 40 mg/dL in M 
and < 50mg/dL in 
F) 
Raised plasma TG 
(≥150 mg/dl) 
and/or low HDL-
cholesterol (<35 
mg/dl for M and 
<39 mg/dl for F) 
Obesity  
(WC - M: ≥94 cm 
(37 inches) for  
and F: ≥ 80 cm 
(32 inches)) 
TG ≥ 150 mg/dL  Prothrombic 
factors 
Systolic blood 
pressure ≥ 130 
mmHg or 
diastolic blood 
pressure ≥85 
mmHg 
Elevated GLC > 
100 mg/dL 
Elevated BP (SBP 
≥ 130 mm Hg or 
DBP ≥ 85 mm 
Hg)  
Central obesity  Hypertension (BP 
≥140/90mm Hg) 
HDL-c < 40 
mg/dL 
Markers of 
inflammation  
Fasting glucose > 
100 mg/dL 
including diabetes 
and those with a 
prior diagnosis of 
or treatment of 
any of these 
conditions 
 Elevated GLC 
(>100 mg/dL) 
including patients 
taking medication 
to manage 
hypertriglyceride
mia, low HDL-c, 
hypertension and 
hyperglycemia 
Microalbumin-
uria 
Dyslipidemia (TG 
≥180 mg/dl or 
HDL-c ≤ 39) 
 Endothelial 
dysfunction 
   
Adapted from LeRoith and Cohen and Alberti, et al.  (57, 58). 
Abbreviations: M: Males; F: Females 
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Chapter 3 
Evaluating different waist circumference cutoff criteria for assessment of health risk in a 
sample of young Mexican adults 
Abstract 
Background: Metabolic syndrome (MetS) is a growing problem around the globe that is 
characterized by the concurrent manifestation of three or more of five factors: enlarged waist 
circumference (WC), elevated serum triglycerides (TG), low high-density lipoprotein cholesterol 
(HDL), high blood pressure and impaired glucose tolerance. Ethnicity dependent cutoffs for WC 
have been established, however those designated for the Mexican population have been shown to 
be inadequate for accurately assessing risk for metabolic disease. The WC cutoffs applied to 
Mexicans were established by the International Diabetes Federation (IDF) using data from south 
Asian populations and so are not specific to Mexican populations. Objective: To assess the 
prevalence of MetS and components thereof in a cohort of young Mexican adults in order to 
evaluate the predictive value of different WC cutoffs for risk of metabolic disease. Results: The 
IDF and the proposed set (MEX) showed significant agreement (Kappa = 0.73) for identification 
of individuals at risk. The American Heart Association (AHA) WC criteria showed the least 
agreement with the IDF and MEX criteria (Kappa = 0.57 and Kappa = 0.82, respectively). The 
MEX WC criteria correlated more negatively with HDL (r=-0.20, p=0.05) than the IDF and AHA 
criteria. Additionally, the MEX criteria were found to identify males with higher BMI, TG and 
diastolic blood pressure than the other two criteria. Conclusion: Our study demonstrates that the 
WC cutoff criteria suggested by the IDF may not be adequate for identifying individuals who are 
truly at risk for MetS in this population.  
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Introduction 
Metabolic syndrome (MetS) is a growing problem around the globe that is associated with 
several of the top causes of death worldwide, including ischemic heart disease, stroke and diabetes 
mellitus (1, 2). Although there is still debate regarding certain aspects of the clinical definition of 
MetS, there is overall agreement on the components that contribute to this disease. According to 
the harmonized definition, MetS is characterized by the concurrent manifestation of several of the 
following factors including: elevated triglycerides (TG), low high-density lipoprotein cholesterol 
(HDL), elevated blood pressure (BP), insulin resistance (IR) and enlarged waist circumference 
(WC) (3). This definition stipulates that for a diagnosis of MetS to be made at least three of the 
five factors must be present. However, the 2005 International Diabetes Federation (IDF) 
Worldwide consensus definition of MetS requires central obesity, or elevated waist circumference, 
in addition to two or more of the other factors to be present for diagnosis to be made (4). Another 
distinction among the guidelines for diagnosis of MetS are the WC cutoffs. The IDF has 
recommends using distinct cutoff criteria for different ethnic groups including Europeans and 
Americans while South Asians, Chinese and Japanese all are assessed using the same criteria.  
Specific cutoffs for central and south American, Sub-Saharan African, Mediterranean and Middle 
Eastern populations have not been established (4).  
Measurement of WC is an ideal method of assessing disease risk because it is non-invasive 
and requires little training to administer. Elevated WC, as a proxy for measurement of abdominal 
obesity (AO), is associated with occurrence of several chronic diseases, including cardiovascular 
disease (CVD) and type II diabetes mellitus (T2DM) (5-7). The link between AO and chronic 
disease is the accumulation of fat in the viscera (3). Adipose tissue has been shown to possess 
endocrine properties and is associated with increased inflammation (7). The inflammatory 
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processes that are present with elevated body fatness are linked to increased risk for T2DM, CVD 
and insulin resistance (8). This equates to as much as a two-fold increase in risk for CVD and five-
fold increased risk for T2DM (9). Additionally, the efflux of free fatty acids from hypertrophied 
visceral adipose tissue has been shown to influence liver metabolism. This results in hepatic insulin 
resistance which leads to augmented glucose production in the liver as well as increased production 
of high triacylglycerol-rich lipoproteins (6). Taking into account the damaging effects of AO, 
having a precise measure of AO would aid in the accurate assessment of risk for chronic disease.  
Obesity and central obesity have been increasing in many areas of the world (10). Mexico, 
in particular, is showing a startling growth in prevalence of overweight and obesity. According to 
the 2012 Mexican National Health and Nutrition Survey, 71.3% of adults are overweight or obese 
and 74.0% of overweight or obese adults show elevated WC according to the IDF cutoffs (11), 
which are the current WC cutoff values applied to central and South Americans, including 
Mexicans, are those recommended by the IDF (12). The WC cutoffs recommended by the IDF are 
80 cm in women and 90 cm in men (4). Nonetheless, there is debate whether these are the 
appropriate cutoffs for Mexicans. For example, a study based on a sample population in Mexico 
City, recommended the use of the following cutoffs as better predictors of health status: 84 cm in 
women and 98 cm in men (13). A third set of criteria, published by the American Heart Association 
and the National Heart, Lung and Blood Institute (AHA) were also evaluated by Alonso and 
collaborators for risk detection value in Mexican adults. The WC cutoffs suggested by the AHA 
are 102 cm for men and 88 cm for women (14). 
The current WC cutoffs used to assess AO have been established based on adult 
populations, including a broad age range. Additionally, the current body of research on MetS 
largely focuses on adult populations, typically aged 20 years and older. However, studies show 
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that negative health consequences of obesity are becoming apparent during young adulthood (15-
17). Young adults constitute a commonly overlooked population when it comes to this work as 
well as public health initiatives for health screening and disease prevention. Furthermore, studies 
have demonstrated that the young adult and adolescent Mexican population is at even greater risk 
than their U.S. counterparts at developing CVD at younger ages (18, 19). Therefore, there is a need 
for more specific screening methods for detecting risk for MetS and CVD in young Mexican adults.  
Our unique population of young Mexican adults offers an opportunity to examine the 
effectiveness of the currently used diagnostic criteria for MetS at detecting health risk in younger 
individuals. According to the AHA, preventative measures should be implemented as early as 
possible to have the greatest effect, therefore identifying at-risk individuals early in life is 
important (20). Therefore, the objectives of this cross-sectional study were as follows: 1) to 
examine the prevalence of risk factors for MetS in a population of young Mexican adults; 2) to 
examine the association between elevated WC, according to the IDF, AHA and the proposed MEX 
cutoffs, and the other components of MetS; 3) to evaluate the sensitivity and specificity for three 
sets of WC criteria for identifying individuals who are at risk for MetS in this young adult 
population. We hypothesized that the MEX cutoffs would be more strongly associated with the 
occurrence of abnormal values of the other components of MetS than the IDF and AHA cutoffs.  
Subjects and Methods 
Study Participants 
Study participants were applicants to the Autonomous University of San Luis Potosi 
(Universidad Autonoma de San Luis Potosi [UASLP]) located in San Luis Potosi, Mexico. The 
majority of applicants were residents of the metropolitan area as well as surrounding cities. Data 
was collected between February and July 2009 for the 2009-2010 academic year. A total of 668 
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(300 male, 368 female) applicants aged 18-25 years were included in this study. Applicants 
undergo a mandatory health screening at the UASLP health center during the application process 
(21). Informed consent to use information collected during the health screen was obtained from 
each participant. The screening included anthropometric measurements, complete medical history 
and physical exam performed by a physician and a blood draw taken by nursing staff. All data was 
collected in accordance with the Institutional Review Board standards for both UASLP and 
University of Illinois at Urbana-Champaign (UIUC) and are part of the Universities of San Luis 
Potosi and Illinois: A Multidisciplinary Investigation on Obesity, Genetics and Socio-Environment 
(UP AMIGOS) project. 
Anthropometric Measures 
 Anthropometric measurements were taken by trained staff at the UASLP health center. 
Training for staff on the proper and consistent measurement of height, weight and blood pressure, 
was conducted annually by the principal investigators of the UP AMIGOS project in a workshop 
held at UASLP. Height was measured using a stadiometer and recorded to the nearest centimeter. 
Weight was measured using a calibrated scale and recorded to the nearest 0.1 kg (Torino, Tecno 
Lógica, Mexicana, Mexico). WC was measured according to an established protocol published by 
the International Chair on Cardiometabolic Risk (22). Consistent measurement of WC is critical 
for use of this measure for epidemiological studies. The location of measurement is not critical for 
comparison purposes as long as the measurement is taken from the same anatomical location for 
each subject (23). Participants were first asked to clear the hip and waist region of clothing and 
staff palpated the hip region to locate the superior edge of the iliac crest. A non-elastic measuring 
tape was wrapped around the participant at the top of the iliac crest perpendicular to the floor and 
WC was recorded to the nearest tenth of a centimeter. A diagram outlining the steps for proper 
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WC measurement, translated into Spanish, was posted in all exam rooms at the UASLP health 
center for staff to use as a reference. The English version is provided in Appendix A. 
Blood Pressure 
 Blood pressure was measured by certified healthcare providers according to the standard 
protocol recommended by the American Heart Association. Blood pressure was measured using 
Welch Allyn cuffs while the participant was in the sitting position. Measurement was taken from 
the dominant arm, which was the right arm in the majority of cases. Both systolic and diastolic 
blood pressure were recorded as reported previously (24).   
Blood Sample Collection and Biomarker measurement 
 Blood samples were collected from individuals after an overnight fast. Fasting glucose was 
measured via the glucose oxidase peroxidase GOD-PAP method using the Alcyon 300 auto 
analyzer (Abbott Park, IL, USA). Reagents were acquired from BioSystems (Barcelona, Spain). 
TG levels were measured by the glycerol phosphate oxidase peroxidase method based on a 
colorimetric enzymatic reaction. HDL concentration was determined by direct measurement using 
a detergent to solubilize the HDL which was then quantified spectrophotometrically according to 
the cholesterol oxidase method. All blood biomarker measurements were conducted at the UASLP 
clinical chemistry laboratory, which is a state certified reference laboratory for blood analysis in 
San Luis Potosi, Mexico.  
Metabolic Syndrome Criteria 
The variables examined in this analysis included measured systolic (SBP) and diastolic 
blood pressure (DBP), WC, HDL, TG, and fasting blood glucose (GLC). The IDF definition of 
MetS requires elevated waist circumference in addition to the presence of at least two of the other 
four criteria for diagnosis to be made. The AHA and MEX criteria do not have this requirement. 
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For MetS to be diagnosed using the AHA and MEX criteria, three of the five conditions must be 
present. However, the same five variables are common to all three definitions of MetS included in 
this analysis and these are summarized in Table 2. 
Table 2. Diagnostic criteria for Metabolic Syndrome according to IDF, AHA and MEX. 
Components of MetS IDF(4) AHA(14) MEX(13) 
WC 
Men ≥ 90 cm                                                
Women ≥ 80 cm 
Men ≥ 102 cm                                        
Women ≥ 88 cm 
Men ≥ 98 cm                                                
Women ≥ 84 cm 
 All MetS definitions 
TG > 150 mg/dL (1.7 mmol/L) 
HDL 
Men < 40 mg/dL (1.03 mmol/L) 
Women < 50 mg/dL (1.29 mmol/L) 
BP Systolic ≥ 130 mmHg                    Diastolic ≥ 85 mmHg 
GLC Fasting Glucose ≥ 100 mg/dL (5.6 mmol/L) 
 
Statistical Analysis 
Statistical analysis was carried out using SAS 9.3 (SAS Institute Inc., Cary, NC, USA). 
Statistical significance was assessed at p-value<0.05 for all tests. All variables were assessed for 
normality using the Shapiro-Wilk test prior to analysis. TG were found to be non-normally 
distributed and were log (10) transformed. Degree of risk were categorized as follows using the 
MEX and AHA MetS criteria: a) individuals who did not meet the criteria for MetS (≤ 2 criteria), 
b) those that met more than three of the criteria excluding the WC criteria and c) those that met 
two or more of the criteria including WC. IDF standards require that elevated WC be present for 
a diagnosis of MetS, so risk was assessed as those with MetS who met two or more criteria with 
elevated WC and those without elevated WC.  Cohen’s Kappa was utilized to assess the agreement 
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among the three MetS definitions, comparing the IDF to AHA, IDF to MEX and MEX to AHA 
definitions, respectively.  Levels of agreement, low (<0.40), medium (0.41-0.60) and high (>0.60), 
were assessed according to Viera et al. (25). Pearson correlations, rho values, were used to compare 
the predictive value of each of the WC cutoffs in each of the different sets of criteria with incidence 
of undesirable levels of the other components of MetS, as well as BMI. Correlations were 
performed using the entire cohort and then among males and females individually. In all cases, 
Pearson correlations were adjusted for the calculated age of the participants and were conducted 
separately by sex. General linear models were used to assess the mean difference in BMI and the 
other components of MetS in those individuals identified as having elevated WC according to the 
IDF, AHA and MEX definitions. The general linear models were adjusted by age and sex.  
 
Results  
 Figure 2 shows the prevalence of MetS and each component by gender and according to 
each set of criteria. The IDF criteria identifies the greatest proportion of individuals, both males 
and females, as having MetS with 9.7% (n=29) of males and 12.2% (n=45) of females identified 
as having MetS. The AHA and MEX criteria identified 4.3% (n=13) of males, 8.4% (n=31) of 
females and 6.3% (n=19) of males and 10.3% (n=38) of females, respectively. The most prevalent 
MetS component in this cohort was low HDL, with females showing higher prevalence (52.5%, 
n=193) than males (26.7%, n=80). Table 3 summarizes the anthropometric and lipid profile 
characteristics of our entire cohort as well as the individuals identified as having elevated WC 
based on the IDF, AHA and MEX criteria.  
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Figure 2. Prevalence of MetS and components of MetS in men and women according the IDF, 
AHA and MEX cutoff criteria.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2A: Prevalence (%) of MetS   according to the IDF, AHA and MEX criteria in males and females.  
Fig. 2B: Prevalence (%) of elevated WC according to the IDF, AHA and MEX WC criteria in males and females.  
Fig. 2C: Prevalence (%) of components of MetS in males and females. 
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Table 3. Population characteristics: Components of Metabolic Syndrome. There are no significant differences in age, BMI and TG 
between males and females. However, differences were shown between the sexes in WC, SBP, DBP, HDL and GLC.  
 
Variables 
Whole Cohort 
N = 668 
IDF 
N = 224 
AHA 
N = 88 
MEX 
 
N=137 
Age (years) 18.47 (1.34) 18.70 (1.54) 18.78 (1.56) 18.70 (1.55) 
BMI (kg/m2) 23.86 (4.54) 28.07 (4.21) 30.89 (3.90) 29.17 (4.51) 
WC (cm) 80.36 (11.85) 92.81 (9.24) 99.99 (8.45) 96.06 (9.40) 
SBP (mmHg) 111.63 (8.72) 114.49 (9.56) 116.36 (8.63) 115.18 (9.65) 
DBP (mmHg) 72.72 (6.90) 74.42 (6.93) 75.57 (6.58) 74.82 (7.39) 
TG (mg/dL) 111.60 (59.72) 136.87 (74.97) 146.06 (77.46) 141.25 (75.73) 
HDL (mg/dL) 171.08 (33.35) 44.48 (10.51) 42.72 (9.85) 43.77 (10.62) 
GLC (mg/dL) 90.15 (8.18) 91.33 (9.13) 90.53 (9.13) 90.54 (9.15) 
 
Data are mean (standard deviation). BMI: Body mass index; WC: Waist circumference; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; TG: 
Triglycerides; HDL: High-density lipoprotein, GLC: Fasting blood glucose. 
3
3 
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There was strong agreement between the IDF and MEX criteria for detection of MetS 
(Kappa = 0.73) and between the AHA and MEX criteria (Kappa = 0.82). However, the IDF and 
AHA criteria showed medium agreement for MetS detection (Kappa = 0.57). Pearson correlations 
between the WC cutoffs and each of the other components further clarified the disparities in 
detection of MetS between the three sets of criteria. The rho values for the correlations of WC for 
males and females with each component of MetS and BMI by the IDF, AHA and MEX criteria are 
summarized in Table 4. BMI was strongly correlated with the WC cutoffs across all sets of criteria, 
although the IDF (r=0.74, p<0.0001) and AHA (r=0.74, p<0.0001) showed stronger correlations 
in males than females using the MEX (r=0.69, p<0.0001) criteria. The IDF (r=0.76, p<0.0001) and 
MEX (r=0.74, p<0.0001) correlated higher with BMI in females than those identified by the AHA 
(r=0.61, p<0.0001) WC criteria. SBP shows significant correlation with WC in females identified 
by the IDF (r=0.40, p<0.0001) and MEX (r=0.37, p<0.0001) criteria but not the AHA (r=0.23, 
p>0.05) criteria. Significant correlation between WC and SBP according to any of the WC criteria 
was no observed in males. Elevated WC was significantly correlated with increased DBP in and 
females identified by the IDF (r=0.25, p<0.005) and MEX (r=0.26, p<0.05) criteria. Additionally, 
significant negative correlation was observed between WC and HDL for females in both IDF (r=-
0.19, p<0.05) and MEX (r=-0.20, p<0.05) criteria. No significant correlation was observed 
between any of the WC criteria and GLC. 
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Table 4. Pearson Correlations (rho values) of individuals with elevated waist circumference with 
other components of MetS by sex. 
 
Variables 
IDF  
Males 
N = 84 
IDF  
Females 
N = 140 
AHA 
Males 
N = 23 
AHA 
Females 
N = 65 
MEX  
Males 
N = 36 
MEX 
Females 
N = 101 
BMI (kg/m2) 0.74c 0.76c 0.74c 0.61c 0.69c 0.74c 
SBP (mmHg) 0.05 0.40c 0.05 0.23 -0.13 0.37c 
DBP (mmHg) 0.01 0.25b 0.01 0.16 -0.13 0.26a 
TG (mg/dL) 0.05 0.17a 0.05 -0.08 -0.16 0.14 
HDL (mg/dL) -0.06 -0.19a -0.06 -0.13 -0.09 -0.20a 
GLC (mg/dL) -0.15 0.01 -0.15 0.04 -0.16 0.06 
 
ap-value < 0.05 bp-value < 0.005 cp-value <0.0001. Abbreviations: SBP: Systolic blood pressure; DBP: Diastolic blood 
pressure; TG: Triglycerides; HDL: High-density lipoprotein, GLC: Fasting blood glucose. 
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To further characterize the relationships between WC and the other components of MetS, 
general linear models were used to compare the individuals uniquely identified as at risk by each 
of the WC cutoff criteria. The general linear models show, in males, that mean BMI is different 
between the IDF, AHA and MEX WC cutoff criteria (27.9 ± 2.6, 30.6 ± 2.5 and 33.0 ± 3.3 kg/m2, 
respectively). Furthermore, the AHA criteria and MEX criteria captured individuals with a 
significantly higher BMI than the IDF criteria (p<0.0001 and p=0.003 respectively). Mean TG of 
individuals distinguished by the MEX criteria was higher (175.4 mg/dL) than those detected by 
the IDF (123.6 mg/dL) criteria (p=0.0073). The IDF WC criteria identified individuals with lower 
mean DBP (75.8 ± 6.1 mmHg) than both the AHA (79.6 ± 3.7mmHg) and MEX (81.5 ± 8.0mmHg) 
criteria (p=0.0031 and p=0.0193 respectively). Figure 3 shows the graphical representation of 
these relationships. 
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Figure 3. Comparison body mass index (BMI), triglycerides (TG) and diastolic blood pressure (DBP), all components of metabolic 
syndrome (MetS), of males with elevated WC based on IDF, AHA and MEX criteria.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
--- Indicates the cutoff for normal levels: BMI: 25 kg/m2, TG: 150 mg/dL, DBP: 85 mmHg 
Lettered bars indicate significant difference (p value < 0.05). 
Panel A: comparison of mean BMI of males with elevated WC by each of the three MetS criteria.  
Panel B: comparison of mean TG of males with elevated WC by each of the three MetS criteria.  
Panel C: Comparison of mean DBP of males with elevated WC by each of the three MetS criteria. Both the AHA and the MEX WC cutoffs identify individuals 
with DBP that are significantly higher than IDF, however the mean DBP of the AHA and MEX criteria were not significantly different. 
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Discussion 
The objective of this study was to examine the correlation of WC cutoffs from three sets 
diagnostic criteria for MetS with values of the other components of MetS. Our aim was to identify 
which of these sets, either the IDF, AHA or the MEX criteria, most accurately identified 
individuals at heightened risk for MetS in this population. We hypothesized that the proposed set 
of WC criteria would more accurately identify individuals at increased risk for MetS. To 
accomplish our aim we examined the groups identified as having elevated WC by each set of WC 
cutoffs. The IDF, AHA and MEX criteria defined elevated WC in men and women as follows: ≥90 
cm, ≥102 cm and ≥98 cm in men and ≥80cm, ≥88 cm and ≥84 cm in women, respectively.  
In order to accurately describe this cohort, we assessed the prevalence of each component 
of MetS. It has been shown that there are marked differences in prevalence of MetS components 
and the most prominent components are different between males and females. NHANES showed 
that of 2012, in the U.S. 32.8% of males and 36.6% of females over 20 years of age have MetS 
according to the NCEP cutoffs (26). The WC criteria used are the same as the AHA. Moreover, 
Hispanics aged 20 to 39 years showed a prevalence of 18.3% and approximately 21% had MetS 
(26). In comparison, in our cohort of young adults, aged 18 to 25, 19.6% of males and 18.2% 
females have MetS by the AHA definition.  Furthermore, a study involving an adult population, 
aged 16 and over, from northern Mexico indicated that elevated WC and lowered HDL are the 
most prevalent components of MetS in Mexicans. The authors segregated their cohort by age group 
and in so doing showed that lowered HDL is the most prevalent abnormality among individuals 
between the ages of 16 and 25 years of age (27). Our cohort of young adults mirrors their findings 
in that HDL is the most prominent factor, especially in women, and WC the second most prevalent.  
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We then tested the agreement among the three sets of criteria. We expected the differences 
in WC cutoffs to change not only the number but show marked differences in the metabolic 
characteristics of the groups identified as having elevated WC. We found that the MEX criteria 
shared strong agreement with both the IDF and AHA criteria, however the IDF and AHA showed 
a much weaker agreement. This result is as anticipated since the MEX WC cutoffs, numerically, 
fall in between the other WC cutoffs defined by the IDF and AHA. Next, we examined the 
correlations between WC cutoff criteria of each set and the other components of MetS including 
SBP, DBP, TG, HDL, and GLC. Our findings demonstrate that, in females with elevated WC, the 
MEX WC cutoffs correlate more highly with lowered HDL and elevated DBP than the IDF WC 
cutoff criteria. This has important implications on for the assessment of health of the Mexican 
population as the IDF WC cutoffs are currently recommended by the National Institutes of Health 
in Mexico. Similarly, in males isolated by the MEX WC cutoffs, those with WC greater than 98 
cm, overall have higher BMI, SBP, DBP, TG lower HDL and higher GLC. Additionally, applying 
the MEX WC criteria in the diagnosis of MetS uniquely identified men with a mean TG level 
above the cutoff for normality. Hence, although the MEX WC criteria are not as highly correlated 
with the other components of MetS as the IDF criteria, our results indicate that the MEX WC 
cutoff criteria more accurately identify individuals that are truly at increased risk and in need of 
intervention. 
Using WC as an indicator for metabolic disease risk is advantageous in that it is highly 
simple to administer, non-invasive to patients and associated with health outcomes (5). We found 
high correlates with DBP, an important indicator of cardiovascular health and according to a study 
examining low DBP in veterans maintaining DBP between 70 to 86 mmHg was optimum for 
preventing cardiovascular events (28). Also, a study using data from the second generation of the 
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Framingham Heart Study showed that DBP is a more prominent predictor for CVD risk in 
individuals under the age of 45 years (29). It is evident, therefore, from our findings and that of 
the aforementioned studies that there is imminent risk for adverse health outcomes in this young 
population. Thus, it is important to use criteria that are both specific to the population and sensitive 
enough to identify those at high risk and in need of intervention. Although WC alone does not 
measure true metabolic healthiness it does serve as a valid indicator of increased risk (30). A study 
examining the sensitivity and specificity of AO diagnostic criteria have determined that WC 
cutoffs should be carefully constructed based on the population for which they are targeted (13).  
Elements of metabolic syndrome are influenced by lifestyle factors and so are excellent 
targets for early intervention. The American Academy of Pediatrics (AAP) encourages screening 
to begin in childhood, up to and including 18 year olds, as the negative effects of lipid 
abnormalities and risk for CVD are becoming evident much earlier than previously thought (28). 
It is also the position of the AAP that treatment of dyslipidemia and related conditions should not 
only be administered on an individual level but also on a population basis (31). Guidelines 
published by academic groups and evidence-based documentation are the first line of defense 
against these conditions. The American Heart Association cites prevention as the best way to 
combat the increasing number of people suffering from metabolic and CVD (28).  
Regarding the differences in correlations between males and females, it is well established 
that adipose tissue deposition is vastly different in men versus women. This accounts for the 
difference in WC which also is associated with differences in disease risk. Men are at higher risk 
for CVD, high blood pressure and increased insulin resistance than women (32). Specifically, 
studies have also shown that blood pressure is dependent on the height of the individual, with taller 
persons showing higher blood pressure than their shorter counterparts (33). Men, in general, are 
 
 
41 
 
taller than women and have exhibited higher blood pressure readings. These differences are not 
unique to adult populations, according to one study including data from NHANES and a cross-
sectional study of children and adolescents, differences in the lipid profile between males and 
females become evident upon the onset of puberty, with females generally showing higher levels 
of blood lipids than males, however this relationship reverses with age (34). This further justifies 
the need for more specific screening tools for young adults and adolescents.  
The importance of identifying WC cutoffs that accurately predict risk in this population is 
that these measures are tools for public health entities to allocate resources to those that truly need 
them. Although, the number of individuals with health insurance has increased in Mexico, it has 
not been accompanied with an increase in access to medical care and it has been reported that 
preventative care is still seriously lacking in many subpopulations (35). Therefore, it would stand 
to reason that with limited resources it is important for criteria to be sensitive and specific in that 
they, not only identify at-risk populations, but also do not include individuals that may not be at 
as great of risk. This ensures that limited resources are being allocated appropriately. The need for 
ethnicity specific WC cutoff criteria is also supported by the body of literature that encourages use 
of previously established specific WC cutoffs (4). To adequately assess risk in a population, the 
standards used should be customized to accurately and precisely predict the occurrence of disease. 
Our work serves to show that the standards currently used to assess WC as a proxy for metabolic 
disease risk in the Mexican population should be reevaluated. With the startling increase in 
occurrence of MetS and metabolically related disease in the Mexico it is important for health care 
providers to be able to assess that risk and intervene as early as possible. 
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Chapter 4 
Individual genetic variations upstream and within the β, β-carotene-15,15-oxygenase 1 
(BCO1) gene locus are associated with the lipid profile in young Mexican adults 
 
Abstract 
Introduction: Retinoids are critical in facilitating many physiological functions from cell 
differentiation to lipid metabolism. The availability of retinoids for body processes is in part 
dependent on the activity of β, β-carotene-15, 15-oxyegenase 1 (BCO1). It has been established 
that single nucleotide polymorphisms (SNPs) near the BCO1 locus confer changes in the efficiency 
of conversion of β-carotene (BC) to retinol in Europeans. To date, no studies have examined the 
association between the BCO1 genotype and the lipid profile in Mexicans. We hypothesized that 
genetic variations in BCO1 will show associations with the lipid profile of young Mexican adults. 
This relationship is under the influence of covariates including dietary intake. Objective: Describe 
the relationship between the lipid profile in young Mexican adults and five BCO1-SNPs and 
examine how dietary intake of fat and carotenoids may affect this relationship. Results: Five 
SNPs, (rs6564851, rs6240424, rs10048138, rs12934922, rs7501331) known to change in BCO1 
enzymatic activity were explored. Significant associations were found for BCO1-rs6564851 G-
allele and the rs6420424 A-allele with increased total cholesterol (TC), low-density lipoprotein 
(LDL) and non-high-density lipoprotein (non-HDL) levels (p-value<0.05). This relationship was 
strengthened when intake of dietary fat and carotenoids were accounted for in the statistical 
models. Conclusion: Our results show that genetic variability near the BCO1 locus was associated 
with blood lipids and that is relationship is mediated by dietary intake of fat and carotenoids. Future 
studies should explore the physiological mechanism of this association in humans. 
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Introduction  
 
Vitamin A is a term used to describe a group of compounds that demonstrate the activity 
of retinoids in vivo. Structurally, retinoids, such as retinol and retinoic acid, are comprised of a 
polyene chain with a cyclic side group with various other side groups that distinguish each 
compound and give them unique biological function. While preformed vitamin A can be derived 
from meats such as liver and dairy products; most commonly, these vitamin A is acquired through 
conversion of provitamin A (ProA) carotenoids. ProA carotenoids include β-carotene (BC), α-
carotene (AC) and β-cryptoxanthin (BCr) to retinol (1). Studies indicate that the bioavailability of 
BC is influenced by the fat content of the diet, timing of meals, dosage as well as interindividual 
variability in absorption (2, 3). Once carotenoids are absorbed, conversion of BC and other ProA 
carotenoids to vitamin A is dependent on the action of enzymes in the intestinal mucosal cells and 
other tissues (4).    
Retinoids, such as vitamin A and its derivatives, are vital players in a variety of body 
processes including embryogenesis, cell differentiation and growth, immune function, vision and 
lipid metabolism (5, 6). β,β-carotene-15, 15-oxygenase 1 (BCO1) and β-carotene-9, 10- 
dioxygenase 2 (BCO2) are the two enzymes responsible for the cleavage of ProA carotenoids to 
produce vitamin A and other retinoid derivatives (7). BCO1 is the primary enzyme responsible for 
oxidative cleavage of ProA carotenoids and specifically cleaves BC at its center bond producing 
two molecules of all-trans-retinal. BCO2, on the other hand has wider substrate specificity and 
will cleave other carotenoids. It has been shown, however, that BCO2 can contribute to BC 
metabolism in the absence of BCO1 (8). Availability of vitamin A (all-trans-retinol) and its 
derivatives are dependent on the action of these enzymes. Studies in mice show that Bco1 deficient 
animals exhibit increased BC accumulation; while expression of Bco1 increases retinoic acid 
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stores in the liver, implicating Bco1 as the major converter of BC to vitamin A in mammals (9). 
However, BCO1 and BCO2 show high variability in efficiency, even in tightly controlled in vitro 
conditions and in animals and humans (10).  
According to studies in mice, retinoic acid helps regulate a signaling cascade for hepatic 
lipid metabolism. Fatty acid oxidation is increased in the presence of retinoic acid by way of 
peroxisome proliferator-activated receptor-α (PPARA), retinoid X Receptor α (RXRα), carnitine 
palmitoyltransferase 1 (CPT1) and Uncoupling protein 2 (UCP2) (11). In addition, fatty acid 
synthesis is decreased with lowered expression of Sterol regulatory binding protein 1c (SREBP-
1c) and Fatty acid synthase (FAS) (11). Overall, this results in decreased VLDL in circulation and 
lower liver triglycerides (11). Figure 4 shows this pathway in detail. Additionally, Hessel and 
colleagues demonstrated the role of retinoic acid in diet induced obesity. Mice without Bco1 
activity show increased susceptibility to dyslipidemia and obesity even when supplemented with 
preformed vitamin A (12). The exact mechanisms of the relationship between activity of BCO1 
and lipid metabolism has not been extensively characterized in humans. However, the association 
between intake of vitamin A and the lipid profile has been observed in young Mexican children 
(13).  
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Figure 4: Effects of retinoic acid on hepatic gene expression 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: ProA: Provitamin A; RBP4-TTR: Retinol Binding Protein 4-transthyretin; BCO1: β-carotene oxygenase 1; SREBP-1c: 
Sterol regulatory binding protein 1c; FAS: Fatty acid synthase; PPARα: Peroxisome proliferator-activated receptor α; RXRα: Retinoid 
X Receptor α; CPT1: Carnitine palmitoyltransferase 1; UCP2: Uncoupling protein 2; LXR: Liver X receptor; RXR: Retinoid X receptor; 
RAR: Retinoic acid receptor; RXR: Retionoid X receptor; RA: Retinoic Acid; RARE: Retinoic Acid Response Elements VLDL: Very 
low-density lipoprotein. Adapted from Bonet et al. (11). 
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In humans, single nucleotide polymorphisms (SNPs) have been identified upstream of the 
BCO1 coding region that confer changes in the conversion efficiency of this enzyme (14, 15). 
These SNPS have also shown association with alterations in the plasma levels of carotenoids (16). 
BCO1 expression is regulated by several genes in a negative feedback cascade. ISX, a homeobox 
transcription factor, acts as an inhibitor of BCO1 expression (17). It binds the promotor region of 
BCO1 in response to an increase in post ProA carotenoid conversion products such as retinoic acid 
(18). Changes in this region have been implicated in interrupting the binding of ISX in this region 
of DNA. SNPs identified that confer these changes include rs6564851, rs6420424, rs12934922 
and rs7501331 (14, 15).  
The objective of this study was to examine the associations between SNPs within and 
upstream the BCO1 gene locus and the lipid profiles of young Mexican adults. We hypothesize 
that the SNPs, in conjunction with covariates related to obesity phenotypes, would show 
association with trends in serum lipids. Additionally, we postulate that intake of carotenoids, 
especially ProA carotenoids, will increase the strength of this association. Given the evidence of 
the known regulatory effects of carotenoids and retinoic acid on BCO1 function in vivo, it follows 
that this relationship would influence association between BCO1 and serum lipids (17, 19).  
Subjects and Methods 
Subjects 
 Participants in this study included a convenience sample of 767 individuals, aged 18 to 25 
years, which were applicants to the Autonomous University of San Luis Potosi (UASLP) in San 
Luis Potosi, Mexico. These individuals were part of the 2009 cohort of the Universities of San 
Luis Potosi and Illinois: A Multidisciplinary Investigation on Genetics, Obesity and Social-
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Environment (UP AMIGOS) study. Data collection took place between February and July of 2009 
for admission in the fall of 2009. Subjects included in this study were generally healthy individuals. 
Data collection 
 The application process for admission to UASLP requires that each prospective student 
complete a thorough health screening. Trained professionals collected the following: 1) 
anthropometric measurements including weight, height and waist circumference, 2) a detailed 
medical history, 3) fasting blood sample and 4) food frequency questionnaire.   
Anthropometric measures 
 Staff of the UASLP health center collected anthropometric measurements for each of the 
participants. A stadiometer was used to measure height, which was recorded to the nearest 
centimeter. Weight was measured to the nearest 0.1 kg using a calibrated scale (Torino, Tecno 
Lógica, Mexicana, Mexico). Body mass index (BMI) was calculated and those with extremes of 
BMI, less than 16.5 kg/m2 and greater than 40 kg/m2, were excluded. 
Physical exam and medical history 
 Physicians employed by UASLP met with each participant individually to conduct the 
medical interview. A detailed medical history was taken to specifically assess family history of 
CVD and T2DM in the immediate family (e.g. siblings, parents, grandparents) in addition to the 
administration of a physical exam. 
Blood sample collection and biomarker measurement 
 Blood samples were collected from participants following an overnight fast. All samples 
were processed on the same day as collection at the state-reference laboratory using automatized 
methods. Briefly, fasting blood glucose (GLC) was measured using the glucose oxidase peroxidase 
GOD-PAP method utilizing the Alcyon 300 auto analyzer (Abbott Park, IL, USA). Reagents were 
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bought from BioSystems (Barcelona, Spain). Individuals with GLC greater than 126 mg/dL were 
excluded from analysis. Triglyceride levels were measured via the glycerol phosphate oxidase 
peroxidase method based on a colorimetric enzymatic reaction. HDL concentration was measured 
directly using a detergent to solubilize the HDL which was then quantified spectrophotometrically 
according to the cholesterol oxidase method. All blood biomarker measurements were conducted 
at the UASLP clinical chemistry laboratory, which is a state certified reference laboratory for blood 
analysis in San Luis Potosi, Mexico. Low-Density lipoprotein and very-low-density lipoprotein 
(VLDL) were calculated using validated equations (20, 21). Non-high-density lipoprotein (non-
HDL) was calculated by subtracting HDL from TC.  
Food frequency questionnaire 
 Semiquantitative food frequency questionnaires (FFQ) were filled out by each participant 
under the supervision of a facilitator. Participants were asked about their average consumption of 
foods from different food groups over the previous year. The FFQ utilized for this study was 
validated previously for use in the Mexican population and based on the FFQ developed by Willett 
et al (22, 23). Surveys that were less than 80 percent complete were not considered valid and were 
not included in the dataset. Survey data was entered into the “SNUT” software developed by the 
National Institute of Public Health in Mexico (22). A total of 511 of the 767 individuals provided 
complete questionnaires to be included in this analysis.  
DNA extraction and genotyping 
 Blood samples were collected in the fasting state by trained medical professionals using 
vacutainer tubes containing EDTA. Blood was kept at -80°C until extraction. Genomic DNA was 
extracted from whole blood using commercial DNA extraction kits (Gentra Puregene Blood Kits, 
Qiagen, CA, USA). DNA was subsequently quantified using NanoDrop 2000 (Thermo Fisher 
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Scientific, Wilmington, DE, U.S.). Genomic DNA was stored at -20°C or -80°C until analysis, 
quality was confirmed using PCR. BCO1 SNPs rs10048138 and 6564851 were genotyped using 
predesigned allelic discrimination Taqman assays (Applied Biosystems, Foster City, CA, U.S.). 
Genotypes were assigned using Sequence Detection Software 2.4 (Applied Biosystems). Details 
of the PCR protocol have been described elsewhere (24). BCO1 SNPs rs6420424, rs12934922 and 
rs7501331 were genotyped using Fluidigm® SNP genotyping platform. Briefly, 300 ng of 
genomic DNA was sent to the Functional Genomic Unit of the W.M. Keck Center at the University 
of Illinois for pre-amplification and genotyping. The assay design was constructed on the 
Fluidigm® D3™ website. Genotypes were called using Fluidigm® Genotyping Analysis software 
version 4.1.2 (San Francisco, CA, U.S.) at a minimum of 85% confidence.  
Statistical Analysis 
 Allele frequencies in this cohort were assessed using the allele counting method. SNPs 
must have a minor allele frequency (MAF) of at least 10% to be considered frequent enough in the 
population to show significant effect. Also, divergence from Hardy-Weinberg equilibrium (HWE) 
was identified using χ2 tests with 1 degree of freedom (df). MAF of five SNPs (rs10048138, 
rs6564851, rs6420424, rs12934922 and rs7501331) upstream of and within the BCO1 gene locus 
were examined in this cohort.  
Analysis was carried out using SAS 9.3 (SAS Institute Inc., Cary, NC, U.S.). Each variable 
was examined for normality (Shapiro-Wilk test, skewness and kurtosis test). Non-normal variables 
identified were all variables of the lipid profile, except HDL, and calories per day as well as total 
and individual carotenoid intake per day (total and individual carotenoids included β-carotene, α-
carotene, β-cryptoxanthin, Lycopene and Lutein). Each non-normal variable was log-transformed 
(log10) and means reported here were back-transformed. Percent of calories consumed from fat 
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was calculated using the standard conversion (25). BMI categories (BMIc) were assigned as 
normal with BMI of less than 25kg/m2 and overweight and obese (ow&ob) with BMI greater than 
or equal to 25kg/m2 according to WHO guidelines (26). 
General linear models were used to test associations between genotype for each of the five 
BCO1 SNPs with components of the lipid profile (e.g. TC, TG, LDL, HDL, non-HDL). 
Associations between genotype of the two BCO1 SNPs and phenotype, in this case the lipid 
profile, were first examined under the genotypic model, making no assumptions about the effect 
of each allele. Differences between the carriers of the major allele and minor allele homozygotes 
of rs6564851 and ra6420424 in mean TC, TG and non-HDL suggested that effect of these SNPs 
follows the dominant genetic model. The assumption under the dominant model was that one allele 
has a greater effect on phenotype over the other and that the heterozygotes are under the same 
amount of risk as homozygotes. The adjusted means of the genotypic model associations are 
provided in Appendix B. Groups were created to compare the carriers of the major allele 
(homozygote and heterozygotes) with the minor allele homozygotes. Genotypic models were 
examined and based on the description of genetic association models in a review by Katheryn L. 
Lunetta (27). Covariates used in each model were determined based on previous literature, as noted 
above, and each model was adjusted accordingly. Models were built systematically starting with 
adjustments for age and sex with additional covariates added one by one to determine individual 
effects. A complete list of the models tested in this analysis are provided in Appendix C. An alpha 
level of 0.05 or less was considered significant.  
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Results 
Population Description 
 In our cohort, 37.2% of participants were ow&ob (N=268), of this group 43.3% were male 
and 32.0% were female. The age, BMI and lipid profile of our cohort is summarized in Table 5. 
Student’s T tests were used to elucidate differences between males and females in our population. 
There were no significant differences observed between males and females in age (p=0.20), TC 
(p=0.14), LDL (p=0.36) and non-HDL (p=0.76). However, males had a significantly higher BMI 
(p=0.001), TG (p=0.04), and VLDL (p=0.04) than females but showed significantly lower HDL 
(p<0.0001) than females in this cohort. The anthropometric and lipid characteristics of BMIc were 
also compared by Student’s T-test. Normal and ow&ob individuals showed significant differences 
in all of the variables examined. These results are summarized in Table 6. 
Table 5. Population Characteristics: Average age, BMI and lipid levels in young Mexican adults. 
 
Values reported are means ± standard deviation. Abbreviations: BMI: Body Mass Index, TC: Total cholesterol, TG: 
Triglycerides, HDL: High-density lipoprotein, LDL: Low-density lipoprotein, VLDL: Very Low-Density Lipoprotein, 
Non-HDL: Non High-Density Lipoprotein. 
  
Variables 
All 
N = 767 
Males 
N = 351 
Females 
N = 416 
P-value 
 
Age (years) 18.8 ± 1.3 18.9 ± 1.4 18.8 ± 1.3 0.20 
BMI (kg/m2) 24.1 ± 4.4 24.7 ± 4.6 23.8 ± 4.3 0.0007 
TC (mg/dL)  171.5 ± 34.2 169.5 ± 33.4 173.2 ± 34.7 0.14 
TG (mg/dL) 112.5 ± 60.1 116.3 ± 61.2 109.4 ± 59.1 0.04 
HDL (mg/dL) 49.0 ± 11.3 47.1 ± 10.9 50.6 ± 11.3 <0.0001 
LDL (mg/dL) 100.0 ± 27.8 99.1 ± 27.7 100.8 ± 27.8 0.36 
VLDL (mg/dL) 22.5 ± 12.0 23.3 ± 12.2 21.8 ± 11.8 0.04 
Non-HDL(mg/dL) 122.5 ± 33.0 122.3 ± 33.2 122.8 ± 32.9 0.76 
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Table 6: Comparison of age, BMI and the lipid profile between normal and ow&ob groups. 
 
 
 
 
 
 
 
 
 
 
 
 
Values are mean ± standard deviation. *P-value for T-test between Normal and overweight/obese groups. 
Abbreviations: WC: waist circumference; TC: total cholesterol; TG: triglycerides; HDL: high-density lipoprotein; 
LDL: low-density lipoprotein; VLDL: very low-density lipoprotein; non-HDL: non-high-density lipoprotein. 
 
Minor Allele Frequencies 
 MAF were calculated for each of the five candidate SNPs and compared with reported 
values from the 1000 Genomes and HapMap projects (28, 29). The two SNPs included in this 
analysis closely mirror the MAF observed in European populations reported by the 1000 Genomes 
and HapMap projects, as shown in Table 7. Each SNP was tested for adherence to the HWE, the 
p-value and χ2 values are listed in Table 7. BCO1 rs12934922 was not found to be in HWE in this 
population, therefore was excluded from further analysis. MAF by BMIc were also examined. 
Differences between these groups were on the order of 1-2%, with the minor allele being more 
frequent in the ow&ob category for rs10048138, rs6564851 and rs7501331 and the minor allele 
appearing more frequently in the normal category for rs6420424 and rs12934922. These values 
are reported in Table 8.  
Variables 
Normal 
N = 499 
N (m/f) = 208/291 
Overweight/ obese 
N = 268 
N (m/f) =  143/125 
P-value* 
Age (years) 18.7 ± 1.2 19.1 ± 1.6 0.001 
WC (cm) 74.8 ± 7.3 92.5 ± 10.6 <0.0001 
TC (mg/dL)  167.7 ± 32.7 175.8 ± 34.8 0.0003 
TG (mg/dL) 98.8 ± 41.5 123.1 ± 59.5 <0.0001 
HDL (mg/dL) 51.2 ± 11.1 44.6 ± 10.1 <0.0001 
LDL (mg/dL) 96.5 ± 26.9 103.4 ± 27.2 <0.0001 
VLDL (mg/dL) 19.8 ± 8.3 24.6 ± 11.9 <0.0001 
Non-HDL(mg/dL) 116.3 ± 30.5 130.8 ± 34.0 <0.0001 
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Table 7. MAF of BCO1 SNPs in young Mexican adults in this cohort compared to the populations 
in the 1000 Genomes Project and the HapMap Project. 
  
1000 Genomes1  HapMap2 
UP 
AMIGOS 
HWE 
SNP Allele AMR EUR MEX  CEU MEX MAF χ2 p-value 
rs10048138 A 0.24 0.13 0.21  0.13 0.15 0.33 1.18 0.28 
rs6564851 G 0.54 0.50 0.57  0.56 0.64 0.49 0.22 0.64 
rs12934922 T 0.32 0.44 0.27  0.44 NA 0.29 4.49 0.03 
rs6420424 G 0.51 0.46 0.58  0.53 0.63 0.46 0.76 0.38 
rs7501331 T 0.17 0.23 0.16  0.29 0.14 0.16 1.43 0.23 
 
Values displayed are ratios of allele to total alleles in the population. Abbreviations: MAF: Minor allele frequency; 
HWE: Hardy-Weinberg equilibrium.11000 Genomes Project (29) AMR-American, EUR-European, MEX-Mexican 
(from Los Angeles, CA); 2 HapMap Project (28), CEU-Residents of Utah of Northern European descent, MEX-
Residents of Los Angeles, CA of Mexican descent.  
 
 
Table 8. MAF in BCO1 SNPs by BMIc. 
 
  n Normal Ow&ob 
SNP 
Minor 
Allele 
Normal /  
Ow&ob 
MAF MAF 
rs10048138 A 419 / 253 0.34 0.33 
rs6564851 G 425 / 255 0.48 0.49 
rs12934922 T 390 / 231 0.37 0.26 
rs6420424 G 404 / 238 0.47 0.45 
rs7501331 T 407 / 238 0.15 0.18 
 
Abbreviations: Normal: Normal weight (BMI <25 kg/m2); Ow&ob: Overweight & obese (BMI ≥25kg/m2); MAF: 
Minor allele frequency. 
 
Dietary Intake  
A subset of this cohort (n=511) completed ≥80% of the semiquantitative FFQ, allowing for 
the examination of the dietary intake and macronutrient distribution in this subset from our cohort. 
The intake variables were compared between males and females in this group by Student’s T-test. 
On average, men consumed significantly more calories than women per day while women showed 
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higher average total carotenoid intake per day (p=0.02), which encompasses AC, BC, BCr, lutein 
and lycopene pooled together. Individually, BC intake higher in women was significantly higher 
than men (p=0.006), however there was no significant difference in the other ProA carotenoids 
(AC, BCr). The overall macronutrient distribution was not significantly different between the 
sexes. The mean macronutrient distributions as well as intake of carotenoids are listed in Table 9. 
Table 9: Dietary intake of young Mexican adults in the UP AMIGOS cohort. 
 
Values are means (standard error). *P-value for T-test between males and females. Abbreviations: BC: β-carotene, 
AC: α-carotene, BCr: β-cryptoxanthin. 
 
Associations between BCO1 SNPs and elements of the lipid profile 
General linear models were systematically examined for each of the five SNPs selected 
from the literature. The SNPs presented here were initially chosen based on previous studies that 
demonstrated that rs6564851 and rs6420424 have direct effect on the efficiency of conversion of 
BC to vitamin A by BCO1 (14, 30). The association between BCO1 SNPs and the lipid profile 
became evident when adjusting for age, sex and BMIc as covariates in the models. Associations 
were observed among the three allele groups of BCO1 SNPs rs6564851 and rs6420424 with TC, 
LDL, and non-HDL under the genotypic model. Although not significant, the homozygotes of the 
Intake Variables 
Males 
N = 233 
Females 
N = 278 
p-value* 
Total Calories (per day) 2284.0 (73.7) 1963.8 (49.8) 0.0003 
Calories from Carbohydrates (%) 49.9 (0.6) 51.3 (0.5) 0.09 
Calories from Protein (%) 14.3 (0.2) 14.1 (0.2) 0.44 
Calories from Fat (%) 35.4 (0.5) 36.0 (0.5) 0.34 
All Carotenoids (mg/day) 3530.2 (198.7) 4191.8 (199.1) 0.02 
BC (mg/day) 1498.7 (87.8) 1845.4 (89.8) 0.006 
AC (mg/day) 180.8 (12.1) 191.0 (11.6) 0.54 
BCr (mg/day) 179.1 (13.2) 196.8 (13.3) 0.34 
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G allele of BCO1-rs6564851 and the A allele of BCO1-rs6420424 showed elevated levels of TC, 
LDL and non-HDL compared to the heterozygotes and T allele and G allele homozygotes, 
respectively. The adjusted means for TC, LDL and non-HDL by each group for both BCO1 SNPs 
are provided Table 10. The p-values and R2 values, indicating level of significance as well as 
contribution to variation in the phenotype, for all models as well as p-value of both BCO1 SNPs 
are provided in Appendix D. 
Table 10: Adjusted means of TC, LDL and non-HDL (mg/dL) by genotype group for BCO1 SNPs 
(rs6564851 and rs6420424). 
 rs6564851 rs6420424 
Phenotype G/G G/T + T/T 
p-
value 
A/A A/G + G/G 
p-
value 
N (Males/Females) 78/98 251/296  87/118 225/253  
TC  175.1 (33.3) 168.8 (32.7) 0.07 174.3 (32.7) 169.4 (32.5) 0.13 
LDL  104.4 (28.7) 96.4 (27.1) 0.06 102.0 (28.0) 97.6 (27.5) 0.07 
Non-HDL  126.4 (31.6) 120.1 (31.6) 0.07 125.8 (32.3) 121.0 (31.9) 0.10 
 
Values are adjusted means (SD) for age, sex, and BMIc. Abbreviations: TC: Total cholesterol; LDL: Low-density 
lipoprotein; Non-HDL: Non-high-density lipoprotein. 
 
Associations between BCO1 SNPs and the lipid profile are strengthened when accounting for 
dietary intake of fat as well as ProA carotenoids 
 The literature shows that BC absorption and the action of BCO1 are tightly linked, 
physiologically (18, 19). The second arm of this analysis included the dietary intake of fats as well 
as ProA carotenoids. Given that the negative feedback regulation of BCO1 is tied to availability 
carotenoid and vitamin A derivatives we postulated that including dietary intake as covariates in 
these models would strengthen the associations. 
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First, the effect size of diet on the lipid profile in these models was examined. The p-values 
and R2 values of total calorie intake, percent fat intake and ProA carotenoids individually are 
provided in Appendix E. Accounting for calories alone did not have a significant effect on the 
model, however accounting for percent of calories from fat in conjunction with genotype did reveal 
greater differences in adjusted means of lipid profile values by genotype group. The relationship 
between BCO1 SNPs rs6564851 and rs6420424 and the three elements of the lipid profile (TC, 
LDL and non-HDL) were then examined accounting for percent of calories from fat. The minor 
allele homozygotes for the G allele of BCO1-rs6564851 showed significantly higher mean TC 
(p=0.04), LDL (p=0.03) and non-HDL (p=0.04) than the heterozygotes and the homozygotes of 
the T allele. In this same model, the A allele homozygotes of rs6420424 showed higher TC, LDL 
and non-HDL however these associations were not significant. The adjusted means of TC, LDL 
and non-HDL for both SNPs according to this model are shown in Table 11A. Total carotenoids, 
which encompassed BC, AC, BCr, lycopene and lutein, were then added as a covariate in this 
model. Adjusting for total carotenoid intake demonstrated the strongest effect with the G allele 
homozygotes of BCO1-rs6564851 and the A allele of rs6420424 showing greater mean TC 
(p=0.04, p=0.04), LDL (p=0.03, p=0.03) and non-HDL (p=0.04. p=0.04) by almost 10 mg/dL 
compared to the other genotype groups of both SNPs (Table 11B). The associations increased 
strength of the association for rs6564851 when BC was added as an individual covariate. However 
the associations remained not significant with rs6420424 (Table 11C). 
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Table 11A-C: Adjusted means of TC, LDL and Non-HDL (mg/dL) by genotype group of 
rs6564851 and rs6420424 according to three different models. 
 
A 
 
rs6564851 rs6420424 
Phenotype G/G G/T + T/T 
p-
value 
A/A A/G + G/G 
p-
value 
N (Males/Females) 46/60 144/171  54/79 151/166  
TC  178.3 (34.3) 168.7 (33.3) 0.04 176.0 (33.7) 168.6 (33.6) 0.10 
LDL  104.4 (28.7) 96.4 (27.1) 0.03 103.1 (28.0) 96.6 (27.3) 0.08 
Non-HDL  128.9 (33.1) 120.2 (31.5) 0.04 127.2 (32.4) 120.2 (31.9) 0.10 
B 
 
rs6564851 rs6420424 
Phenotype G/G G/T + T/T 
p-
value 
A/A A/G + G/G 
p-
value 
N (Males/Females) 46/60 144/171  54/79 151/166  
TC  179.9 (34.5) 169.4 (33.3) 0.04 177.3 (33.9) 169.3 (33.6) 0.04 
LDL  105.7 (28.8) 97.1 (27.1) 0.03 104.2 (28.1) 97.3 (27.3) 0.03 
Non-HDL  130.5 (33.2) 120.9 (31.5) 0.04 128.4 (32.5) 121.0 (31.9) 0.04 
C 
 
rs6564851 rs6420424 
Phenotype G/G G/T + T/T 
p-
value 
A/A A/G + G/G 
p-
value 
N (Males/Females) 46/60 144/171  54/79 151/166  
TC  179.4 (34.5) 169.2 (33.2) 0.03 176.8 (33.8) 169.3 (33.7) 0.69 
LDL  105.0 (28.7) 97.0 (27.0) 0.02 103.6 (27.9) 97.3 (27.2) 0.66 
Non-HDL  129.9 (33.2) 120.8 (31.4) 0.03 127.9 (32.4) 120.9 (31.9) 0.92 
 
Fig. 7A: Mean (SD) values adjusted for age, sex, BMIc, and percent calories from fat. 
Fig. 7B: Mean (SD) values adjusted for age, sex, BMIc, percent calories from fat and total carotenoids (AC, 
BC,BCr, Lycopene, Lutein). 
Fig. 7C: Mean (SD) values adjusted for age, sex, BMIc, percent calories from fat and BC. 
Abbreviations: TC: Total cholesterol; LDL: Low-density lipoprotein; Non-HDL: Non-high-density lipoprotein. 
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Discussion  
 The objective of this study was to examine the relationship between SNPs within and 
upstream of the BCO1 gene locus and the lipid profiles in young Mexican adults. We hypothesized 
that genotypes that have been previously linked to decreased BCO1 activity will be associated 
with aberrations in the lipid profile. Secondly, we postulated that accounting for dietary intake of 
carotenoids, especially the ProA carotenoids (BC, AC and BCr), will strengthen this relationship 
when the model is adjusted by percent of calories consumed from fat as well.   
This population of young Mexican adults is generally healthier than adults in Mexico as a 
whole. The prevalence of overweight and obesity (ow&ob) in this cohort was 37.2%, being little 
more than half of that observed in the 2012 ENSANUT (71.3%). However, the difference in BMI 
between the sexes suggests an unequal distribution of weight status with males, on average, having 
higher BMI and showing a greater prevalence of ow&ob than females. This is contrary to the trend 
in the adult Mexican population as a whole, according to the ENSANUT 2012, which shows a 
higher prevalence of ow&ob in women (73.0%) than in men (69.4%) (31). The mean values for 
lipid profile variables in this cohort are generally lower than what was observed in the ENSANUT 
2006 countrywide. The mean TC, TG, LDL and HDL in this population are about 20 to 30 mg/dL 
lower than the means of these values found in all adults over 20 included in the nationwide survey 
(32). Vitamin A deficiency is a problem in many countries around the world, and the intake of 
carotenoids in this cohort were well below the recommended daily allowances (RDA) set by the 
Institute of Medicine (IOM) of the National Academies of Sciences (United States), of 900 μg for 
men and 700 µg for women, of retinol activity equivalents (RAE) per day (33). The average total 
intake of carotenoids, not including preformed vitamin A, was 135 mcg RAE and 186 mcg RAE, 
in men and women respectively.  
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In order to study the association between BCO1 and the lipid profile we used systematically 
constructed models that accounted for mediating factors including age, sex, and weight status of 
the individuals. Our results suggest that there is, in fact, a significant relationship between 
genotype of the SNPs, rs6564851 and rs6420424, and TC, LDL and non-HDL in this population. 
These two SNPs were previously shown by others to impact the activity of BCO1 in vivo (14, 15). 
Each SNP was first tested for Hardy-Weinberg equilibrium to ensure that these SNPs are not 
subject to external influences such as nonrandom mating, population stratification or nonrandom 
genotyping error (27). One SNP initially examined in our analysis, rs12934922, did not meet this 
standard and was excluded from subsequent analysis. The two SNPs presented here, rs6564851 
and rs6420424, are in Hardy-Weinberg equilibrium and the minor allele of each occurs in more 
than ten percent of this population. Additionally, these SNPs were chosen based upon their 
significance reported in previous research (14, 30). BCO1 rs6564851 and rs6420424 occur within 
the BCO1 coding and regulatory region and have been shown to decrease the catalytic activity of 
BCO1 in humans (14).  
The literature that describes BCO1 indicates that expression of this enzyme is largely 
governed by a negative feedback regulation loop (18). Levels of post conversion of ProA 
carotenoids down regulate the expression of BCO1 while presence of ProA carotenoids increases 
expression (19). For this reason, we hypothesized that accounting the ProA carotenoids in the diet 
would affect the relationships observed. Indeed, the strength of the association between BCO1 
SNPs and the lipid profile increased in the dominant model when dietary BC was included as a 
covariate. As the bioavailability of carotenoids is increased with the intake of fat, dietary intake of 
fats, was accounted for in these models as well. Our findings confirm the relationship between, 
not only fat intake with the lipid profile but also that the action of carotenoids and the BCO1 
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enzyme can have a measurable effect on atherogenic lipids in serum. Ferrucci et al. showed that 
the minor allele carriers (G-allele) of rs6564851 exhibit higher levels of circulating BC suggesting 
that conversion of BC to retinol was reduced (15). These findings were mirrored by Lietz et al. 
who showed what the A-allele of rs6420424 and the G-allele of rs6564851 resulted in lowered 
conversion efficiency of BC to vitamin A by BCO1 (14). Coupled with findings that higher levels 
of plasma BC are associated with elevated HDL and LDL in NHANES participants, our results 
clearly demonstrate the link between lowered conversion efficiency and increased serum lipid 
levels, specifically of LDL (34). Of particular interest is that the differences in the lipid profile 
among the genotype groups in BCO1 were substantial. We observed almost a 10 mg/dL difference 
in TC, LDL and non-HDL between the groups, in each of the models. A reduction of serum 
cholesterol by this magnitude could mean a decrease of risk for fatal CVD of 3% or more alone, 
but this risk reduction can be greater in the presence of other risk factors (35).  
The lipid profile is also under the influence of genetic, environment and behavioral factors. 
Diet therapy is arguably one of the most prominent intervention strategies in prevention of CVD 
in the media. Physicians and registered dietitians make recommendations for diet change to 
improve any number of factors that affect CVD risk and treatment. The lesson we can take from 
this work is that identification of those individuals with the allele for decreased BCO1 activity, the 
G-allele in rs6564851 and the A-allele of the rs6420424, who are low converters of BC may benefit 
from vitamin A or diet intervention.  
The importance of these findings is that these elements of the lipid profile (TC, LDL and 
non-HDL) are predictive of development of atherosclerosis. Atherosclerosis is a known risk factor 
for myocardial infarction and stroke, two of the top causes of morbidity and mortality in the world 
(36). With the rising numbers of individuals with increased risk for and occurrence of CVD this 
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work highlights an opportunity to intervene. Also, college age is a time of transition to 
independence and the development of habits that are carried on into adulthood. Intervention 
strategies that address the development of healthy eating and lifestyle habits at this stage will likely 
carry on to adulthood (34).  
The landscape of prevention of chronic disease is changing to include the genetic 
components that contribute to development of these conditions. As we move forward, looking at 
the possible genetic contributors to CVD and T2DM will be important in formulating effective 
interventions to ebb the tide of our current medical crisis. Additionally, research is finding that our 
genes are malleable by the environment around them, which opens the door for exploration of the 
interaction between nature and nurture. Examining the connection between nutrition and genetics 
is one such frontier. Our study shows dietary vitamin A and carotenoids coupled with genotype of 
BCO1 are connected to physical outcomes of health. Future studies should examine the effect of 
multiple SNPs within and upstream of BCO1. As the SNPs reported here, rs6564851 and 
rs6420424, appear to have similar effects on the lipid profile depending on genotype. Constructing 
genetic risk score allows for assessment of the effect of multiple genes on a phenotypic outcome.  
Risk for disease is evident at younger ages than previously considered. Longitudinal studies 
that examine the habits of this age group as they progress through their academic careers and 
beyond would better inform researchers on the changes that occur in diet and lifestyle over this 
period. The UP AMIGOS group aims to have long-term follow-up with the participants in this 
study. Thus, with more complete information about how diet and genetics interact to produce 
health-related phenotypes, we can better improve the health of populations around the world.   
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Chapter 5 
Examining the relationship between dietary carotenoids and plasma carotenoids: A pilot 
study using a modified food frequency questionnaire in volunteers from Universidad 
Autonoma San Luis Potosi (UASLP) 
Abstract 
Background: Carotenoids their derivatives play essential roles in many body processes. It is 
important, therefore, to have an accurate understanding of how dietary intake of carotenoids 
translates to circulating levels in the body. Diet assessment is challenging in epidemiological 
studies that address nutrition. However, the food frequency questionnaire (FFQ) is a tool to gather 
as much data as possible about the diet of large populations. The strength of this tool is that it can 
be tailored to specific populations and to capture the intake of particular nutrients. Objective: The 
objective of this pilot study was to determine the feasibility of collecting blood samples, in order 
to compare measured serum with dietary intakes of carotenoids from a tailored FFQ. In addition, 
the relationship between intake and serum levels of carotenoids was examined. Results: Our study 
population (N=20) was different in age and BMI from the larger UP AMIGOS cohort but showed 
a similar macronutrient distribution. Significant positive correlations were observed between the 
estimated dietary intakes of retinol and lycopene with serum levels of α-carotene, lycopene and its 
isoforms. Also, circulating levels of carotenoids were significantly correlated with the lipid profile 
of study participants. Conclusions: The successful execution of this unique data collection 
protocol has proven feasible with the available staff and facilities available to our collaborators at 
the Autonomous University of San Luis Potosi, Mexico. The relationships between dietary intake 
and plasma levels of carotenoids show that assessment of intake of these nutrients is possible using 
a tailored FFQ.  
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Introduction 
 Carotenoids are fat soluble compounds that are obtained from the diet. These 
micronutrients are abundant in plants and contribute to red, yellow and orange pigments. As a 
typical part of the diet, they are present in the serum and tissues of humans and other mammals 
(1). The biological actions of carotenoids are numerous. They have been associated with protection 
against certain cancers and are known to demonstrate antioxidant activity in vitro. Derivatives of 
carotenoids can be linked to immune function, vision, cell differentiation and lipid metabolism (2-
4). Assessing nutritional adequacy of these micronutrients in different populations is important for 
understanding their effect on health. To date, these micronutrients do not have recommended daily 
allowances with the exception of vitamin A and provitamin A carotenoids. The RDA values are 
measured in retinol activity equivalents (5). Vitamin A deficiency has been a global health issue 
and has been the subject of numerous initiatives to improve intake of this nutrient. There are 
approximately 60 compounds that possess vitamin A activity, however, the most abundant in the 
human diet are β-carotene, α-carotene and β-cryptoxanthin (6). Prediction of plasma levels of 
carotenoids and retinol have been challenging due to the variability in bioavailability due to diet 
and conversion efficiency of carotenoids between individuals (7-9).  
 Assessing dietary intake in large groups has met with many challenges (10). There are 
several methods that are currently utilized for this type of data collection, including 3-day diet 
recall, 24-hour recall and food frequency questionnaires (FFQ). Epidemiological studies often use 
FFQ to assess the typical intake of a target population over a specified period of time. These 
questionnaires are generalized to make it feasible to obtain information from the greatest number 
of individuals or to fit a variety of study objectives (11). They include a great variety of food 
options and allow for some customizability. However, having this great flexibility can be 
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detrimental to the accuracy and reliability of the data. Uncertainty in the data can come from 
several sources such as question wording, food options listed in questionnaire and administration 
conditions (12). Minimizing these variables’ effect on the ability of the respondent to complete the 
survey is a crucial aspect of study design.  
 The utility of FFQs is that they allow researchers to examine dietary intake in large 
populations for associations with risk for chronic disease and other health outcomes. FFQ are easy 
and inexpensive to administer and there are software programs that allow for simplified extraction 
of nutrient intake data. Also, these questionnaires can be tailored to different populations or to 
assess particular groups of nutrients (12). One way to measure the accuracy and relevance of data 
collected by a tailored survey is to assess the predictive value for biological outcomes (13). In this 
case, the outcome of interest is how dietary intake of carotenoids is correlated with plasma levels 
in humans. Although research shows that dietary intake is not closely correlated with acute changes 
plasma levels of carotenoids, there have been some studies that show that assessment using a FFQ 
can give an idea of plasma levels, representing a longer period of time (12, 14, 15). A study 
conducted by Farrell et al. compared 4 day food records with the FFQ and found significant 
positive correlations, ranging from r=0.31 for energy intake to r=0.63 for fat intake, between the 
two methods, signifying that the FFQ can allow respondents to report their intake relatively 
accurately (16).  
 A study conducted in women living in Mexico City, Mexico sought to validate a 
questionnaire specifically constructed to assess intake of antioxidants and retinol (13). The FFQ 
used in this study was adapted from Willett et al (17). It included foods that are specific to the 
Mexican population that have relatively high amounts of antioxidants. Romieu and collagues 
found significant positive correlations between intake estimated from this FFQ and plasma levels 
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of carotenoids (13). The objectives of this pilot study were as follows: 1) To assess the feasibility 
of collection of blood samples, in our population, for measurement of beta carotene in serum, 2) 
To estimate intake levels of carotenoids using an tailored FFQ to explore the correlations between 
estimated intake of carotenoids and measured plasma concentrations and 3) To examine the 
correlation between estimated intakes of carotenoids and the serum lipids of healthy Mexican 
adults. As we replicate these procedures in the longitudinal UP AMIGOS cohort the work 
completed here has built the framework that will shape the future of this project.  
Methods 
Subjects 
 Participants in this study were a convenience sample of 21 healthy individuals who were 
employees and students at the Universidad Autonoma de San Luis Potosi (UASLP) in San Luis 
Potosi, Mexico. This sample included in analysis consisted of 10 males and 11 females between 
the ages of 21 to 46 years of age. Informed consent was obtained from each participant prior to 
data collection according to the IRB of both UASLP and the University of Illinois at Urbana-
Champaign (UIUC).  
Anthropometric Measurements 
 Anthropometric measurements were taken by trained students from the La Coordinación 
para la Innovación y Aplicación de la Ciencia y la Tecnología (CIACyT) nutrition program at 
UASLP. Height was taken using a wall mounted, portable stadiometer, subjects were asked to 
remove their footwear before height was measured. Weight was taken using a standard home use 
scale and recorded the nearest tenth of a kilogram. Waist circumference and neck circumference 
were taken using a flexible, non-elastic measuring tape. Waist circumference measurement was 
taken at the top of the iliac crest following normal exhalation. Neck circumference was measured 
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at the level of the laryngeal prominence with the head in neutral position. Both circumference 
measurements were recorded to the nearest 0.2 centimeters. The methods used here followed 
protocols reported previously by Mosely et al (18).  
Food Frequency Questionnaire 
 The FFQ used for this pilot study was an adaptation of the survey used for the UP AMIGOS 
project, which is the same used by the National Nutrition Survey in Mexico (19). The FFQ was 
semiquantitative and were filled out by the nutrition student interviewers for each participant. 
Participants were asked about their average consumption of foods from different food groups over 
the previous year. The FFQ utilized for this study was validated previously for use in the Mexican 
population and based on the FFQ developed by Willett et al (17, 20). Additions to the survey 
included foods that would better assess intake of antioxidants, like carotenoids, and vitamin E 
according to Romieu et al (13). Foods added included queso fresco, plantain, sweet potato, 
pumpkin and prickly pear. In addition, data on cooking methods for all foods was collected to 
assess use of oil in cooking (data not shown). The survey used in this study, in Spanish and English, 
is provided in Appendices F and G. Surveys were administered by trained students from the 
CIACyT nutrition program and entered into SNUT (Systema de Evaluacion de Habitos 
Nutricionales y Consumos de Nutrimentos; developed by the National Institue of Public Health, 
Mexico) nutrition software for nutrient analysis (SNUT).   
Blood Sample Collection 
 The protocol for blood sample collection and processing was developed and optimized to 
minimize oxidation of carotenoids in serum by limiting exposure to light. Light exposure can 
significantly degrade carotenoids obscuring measurement, in some conditions by almost 8% (21, 
22). All participants were fasted at the time of blood draw. Blood was collected into pre-labeled 6 
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mL BD Vacutainer® serum tubes (Betty Mills Company, Inc., Franklin Lakes, NJ, USA). Blood 
was immediately placed in a light tight cooler over ice. Samples were left on ice for 20 minutes to 
allow for clotting, blood tubes were then submerged in the ice until processing. Processing of 
samples took place in low light conditions. Samples were then placed in a clinical centrifuge for 
20 minutes at 3000 rpm. One mL aliquots of serum were taken up by a pipette and placed into 
amber tubes. Serum was stored at -80°C in a labeled light safe box until shipping to our laboratory 
at UIUC. Samples were packed in dry ice during shipping to prevent thawing and upon arrival 
immediately placed back in -80°C until measurement. The complete protocol used for blood 
collection and serum separation can be found in Appendix H.  
Serum lipid measurement 
 Briefly serum was collected after an overnight fast and was processed and stored as 
described above. Details of blood biomarker measurement including total cholesterol (TC), 
triglycerides and high-density lipoprotein (HDL) have been described previously in Chapter 4 of 
this document and by Mosley et al (18). 
Carotenoid extraction from human serum  
 Serum samples were allowed to thaw at room temperature for not more than 30 minutes 
before extraction. Extractions were carried out under amber colored lights using 300 μL of serum. 
Briefly, 300 μL of butylated hydroxytoluene (BHT) at 0.1% was added to serum. Samples were 
extracted three times using 1 mL hexane. Samples were then dried under argon gas and stored at -
80°C for less than 48 hours until analysis. Details of extraction were reported by Campbell et al 
(23).   
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HPLC analysis of carotenoids 
Reverse-phase high-pressure liquid chromatography – photodiode array detector system 
(HPLC-PDA) analysis was used to measure carotenoids as previously described (23). Briefly, 
analytical standards of carotenoids including phytofluene, lycopene, α-carotene, β-carotene, β-
cryptoxanthin and zeaxanthin were used for quantification. Samples were analyzed using HPLC-
PDA (Waters, Milford, MA, U.S.). A C30 reversed phase column (4.6 x 150 mm, 3 μm, YMC, 
Wilmington, NC, U.S.) cooled to 18 °C was used with methyl-tert butyl ether, methanol, and 1.5% 
(w/v) aqueous ammonium acetate mobile phases as described previously (24). Carotenoids were 
identified and quantified via UV spectra, retention times and standard comparison. Lycopene 
(Sigma-Aldrich, Saint Louis, MO, U.S.), phytoene, phytofluene, and ζ-carotene standards were 
purchased (Carotenature, Ostermundigen, Switzerland). Samples were kept at 4 °C on an 
autosampler cooling tray and handled under yellow light to reduce degradation of carotenoids.  
Statistical Analysis 
 Analysis was carried out using SAS 9.3 (SAS Institute Inc., Cary, NC, U.S.). All variables 
were first examined for normality. Non-normal distributed data, including the daily calorie intake 
as well as carotenoid intake, were log (10) transformed prior to analysis. Pearson correlations were 
used to determine the relationship between carotenoid intake and measured serum levels. 
Additionally, the correlations between serum levels of carotenoids and the lipid profile were 
examined. Systematically built statistical models accounted for age and sex in addition to other 
covariates, including adjustment for elements of the lipid profile and weight status. These models 
followed the example of Romieu and collagues where Pearson correlations were adjusted for age, 
BMI, serum cholesterol, serum triglycerides, smoking status and total calorie intake (13). Our 
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analyses differed slightly as the smoking status of the participants in this study was not known. A 
listing of all statistical models tested in the present study are provided in Appendix I.  
Results 
 Comparison was made between the 2009 UP AMIGOS cohort and this group of healthy 
Mexican adults. Variables included age, BMI, estimated dietary intake (energy, percent of calories 
from fat (% fat), and intake of carotenoids) and components of the lipid profile. Significant 
differences between the two cohorts were observed in age, however, there was no difference in 
BMI or the lipid profiles of the groups. The UP AMIGOS cohort is a group of college applicants 
(aged 18 to 25) to UASLP. The group selected here was a convenience sample and no restrictions 
were give on age of the participants. However, upon examination of the intake variables, 
differences were apparent in the percent of calories consumed from fat and total carotenoids, β-
carotene, α-carotene, lycopene and lutein. Pursuant to the example of the study conducted by 
Romieu and colleagues, we examined the differences in the same variables between only the 
females in both groups. The only significant differences observed were in mean age, BMI, and 
percent of calories consumed from fat. These results are summarized in Table 12.  
  
 
 
76 
 
Table 12: Comparison of Age, BMI, dietary intake and lipid profile between the UP AMIGOS 
and Pilot cohorts. 
 
UP AMIGOS 
Cohort 
BC Pilot 
Cohort 
  
N (Females) 463 (231) 20 (11) 
  
Variable Mean 
 
SE Mean 
 
SE 
p-value 
all 
p-value 
females 
Age (years) 18.4 ± 0.08 30.1 ± 2.3 <0.0001 0.002 
BMI (kg/m2) 23.9 ± 0.21 25.3 ± 0.9 0.19 0.01 
%Fat1 36.0 ± 0.35 41.0 ± 1.5 0.004 0.002 
Calories (kcal/day) 2207.4 ± 42.3 2206.7 ± 206.3 0.90 0.15 
Retinol (IU) 3529.9 ± 175.8 2858.8 ± 408.0 0.97 0.90 
Carotenoids (IU) 5199.5 ± 263.1 7632.4 ± 916.2 0.004 0.08 
α-carotene (μg) 309.6 ± 24.6 497.3 ± 95.0 0.01 0.08 
β-carotene (μg) 2296.3 ± 108.6 3610.2 ± 405.7 0.002 0.06 
β-cryptoxanthin (μg) 361.4 ± 24.7 319.1 ± 68.4 0.52 0.34 
Lycopene (μg) 5324.5 ± 265.5 9205.6 ± 1323.0 0.005 0.09 
Lutein (μg) 1057.8 ± 47.5 1441.2 ± 189.8 0.04 0.44 
TC (mg/dL) 170.4 ± 1.63 177.6 ± 8.5 0.37 0.49 
TG (mg/dL)  104.4 ± 3.16 118.3 ± 12.1 0.25 0.99 
HDL (mg/dL) 47.7 ± 0.60 43.2 ± 1.7 0.25 0.51 
LDL (mg/dL)  97.5 ± 1.30 106.9 ± 7.8 0.16 0.19 
VLDL (mg/dL) 20.9 ± 0.63 23.7 ± 2.4 0.25 0.99 
Non-HDL (mg/dL) 120.2 ± 1.57 133.4 ± 7.9 0.10 0.26 
 
Values are mean ± SE (standard error). Abbreviations: BMI: Body mass index; %Fat: Percent of calories consumed 
from fat, IU: International Units; TC: Total cholesterol; TG: Triglycerides; HDL: High-density lipoprotein; LDL: 
Low-density lipoprotein; VLDL: Very low-density lipoprotein; Non-HDL:  Non-high-density lipoprotein.
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 Person correlations showed the relationship between estimated intakes of carotenoids and 
measured plasma carotenoids. To examine the model that was most informative in the study 
conducted by Romieu et al, the covariates in the first model presented here included age, sex, total 
calories, total cholesterol and triglycerides (13). Under this model, significant positive correlations 
were observed between serum retinol and α-carotene (r=0.56, p=0.04) and β-cryptoxanthin 
(r=0.79, p=0.002) as well as between lycopene and α-carotene (r=0.66, p=0.02) and β-
cryptoxanthin (r=0.71, p=0.01). The rho values for the Pearson correlations in this model are 
summarized in Table 13.  
In order to further refine the relationship between intake of carotenoids and measured 
serum carotenoids we adapted new models that accounted for other physiologically relevant 
factors such as dietary intake of fats. The model that yielded the most prominent correlations in 
our pilot cohort included age, sex, percent of calories from fat, total cholesterol and triglycerides. 
Adjusting for percent of calories from fat over total calorie intake alone accounts for the increase 
in bioavailability of carotenoids in the presence of fat in the diet. Significant correlations were 
observed between intake of retinol with all-trans-lycopene (r=0.65, p=0.02), trans-lycopene 
(r=0.66, p=0.02), α-carotene (r=0.67, p=0.02) and β-cryptoxanthin (r=0.74, p=0.006). The positive 
correlation between retinol and α-carotene was strengthened with the adjustment for percent of 
calories from fat. Total carotenoid and β-carotene intake showed significant positive correlations 
with measured zeaxanthin (r=0.62, p=0.03 and r=0.59, p=0.04 respectively), as did intake of α-
carotene and (0.57, 0.56 respectively). Also, total lycopene intake was moderately correlated with 
the different isoforms of lycopene measured in serum: cis-lycopene (r=0.62, p=0.03), all-trans-
lycopene (r=0.58, p=0.05) and total lycopene (r=0.61, p=0.04) and also with α-carotene (0.72, 
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p=0.008) and β-cryptoxanthin (r=0.71, p=0.01). The rho values for correlations in this model are 
summarized in Table 14.  
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Table 13: Rho values Pearson correlations based on the model developed by by Romieu et al (13). 
 
 Estimated intake of carotenoids 
Measured Serum 
Carotenoids 
Retinol Carotenoids α-carotene β-carotene β-cryptoxanthin Lycopene Lutein 
Phytofluene  0.51 0.10 -0.21 0.31 0.17 0.49 0.22 
Cys-Lycopene 0.49 0.08 -0.13 0.22 0.29 0.55 0.30 
All-trans-Lycopene 0.47 0.15 0.08 0.20 0.21 0.46 0.18 
Trans-Lycopene 0.49 0.12 0.00 0.21 0.24 0.50 0.23 
β-Carotene 0.41 -0.07 0.00 -0.06 -0.03 0.41 0.04 
α-Carotene 0.60* 0.26 0.27 0.20 -0.23 0.66* -0.07 
ζ-Carotene 0.49 0.17 0.08 0.18 0.06 0.38 -0.03 
Lutein 0.12 0.17 0.03 0.31 0.37 -0.10 0.45 
Zeaxanthin -0.01 0.01 0.13 0.02 0.06 0.02 0.01 
β-Cryptoxanthin 0.79** 0.34 0.24 0.31 -0.15 0.71* 0.28 
 
* Indicates p-value < 0.05. ** Indicates p-value of <0.01 Data adjusted for: age, sex, BMI total calorie intake, TC and TG. Abbreviations: BMI: Body mass index; 
TC: Total cholesterol; TG: Triglycerides. 
  
7
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Table 14: Rho values for the Pearson correlations adjusted for age, sex, BMI, percent of calories consumed from fat, TC and TG 
 
 Estimated intake of carotenoids 
Measured Serum 
Carotenoids 
Retinol Carotenoids α-carotene β-carotene β-cryptoxanthin Lycopene Lutein 
Phytofluene  0.56 0.06 -0.12 0.21 0.16 0.43 0.13 
Cys-Lycopene 0.63* 0.25 0.13 0.33 0.36 0.62* 0.38 
All-trans-Lycopene 0.65* 0.35 0.30 0.37 0.29 0.58* 0.37 
Trans-Lycopene 0.66* 0.32 0.24 0.36 0.32 0.61* 0.38 
β-Carotene 0.33 0.36 0.41 0.29 0.25 0.49 0.36 
α-Carotene 0.67* 0.48 0.49 0.42 -0.02 0.72** 0.28 
ζ-Carotene 0.50 0.39 0.34 0.37 0.24 0.44 0.24 
Lutein 0.35 0.56 0.48 0.61* 0.50 0.26 0.70* 
Zeaxanthin 0.44 0.62* 0.64* 0.59* 0.28 0.51 0.64* 
β-Cryptoxanthin 0.74** 0.49 0.46 0.44 0.08 0.71** 0.38 
 
* Indicates p-value <0.05. Model includes covariates age, sex, BMI, percent of calories from fat, TC and TG. 
Abbreviations: BMI: Body mass index; TC: Total cholesterol; TG: Triglycerides. 
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Table 15: Rho values of correlation between the lipid profile and measured plasma carotenoids in Mexican adults. 
 
 Serum Lipids 
Measured Serum 
Carotenoids 
TC LDL HDL TG Non-HDL VLDL 
Phytofluene  0.14 0.002 0.29 0.25 0.07 0.25 
Cys-Lycopene 0.20 -0.02 0.51 0.31 0.08 0.31 
All-trans-Lycopene 0.20 0.09 0.40 0.17 0.12 0.17 
Trans-Lycopene 0.20 0.05 0.45 0.23 0.11 0.23 
β-Carotene 0.55* 0.56* 0.42 -0.17 0.53* -0.17 
α-Carotene 0.27 0.36 0.24 -0.21 0.25 -0.21 
ζ-Carotene 0.37 0.30 0.18 0.15 0.38 0.15 
Lutein 0.20 0.24 0.31 -0.23 0.15 -0.23 
Zeaxanthin 0.21 0.20 0.28 -0.04 0.17 -0.04 
β-Cryptoxanthin 0.51 0.45 0.33 0.04 0.51 0.04 
 
  * Indicates p-value<0.05. Model adjusted for age, sex and BMI.  Abbreviations: TC: Total cholesterol; LDL: Low-density lipoproteins; HDL: High-density 
lipoprotein; TG: Triglycerides; Non-HDL: Non-high-density lipoprotein; VLDL: Very Low-density lipoprotein. 
8
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Significant correlations were observed between serum β-carotene levels and the lipid 
profile in this sample of volunteers: TC (r=0.55, p=0.03), LDL (r=0.55, p=0.03) and non-HDL 
(r=0.53, p=0.04). The covariates adjusted used to evaluate these relationships included adjustments 
for sex, age and BMI. The rho values for the correlations between all of the measured carotenoids 
and all components of the lipid profile are summarized in Table 15.  
Discussion 
 The objective of this study was to establish a protocol for collecting blood and dietary 
intake information in order to examine the correlations between estimated intakes of carotenoids 
with measured serum levels in Mexican adults. As we replicate these procedures in the longitudinal 
cohort of the UP AMIGOS project, the work completed has served to build the framework that is 
shaping this next phase. The specific method for blood collection required to effectively measure 
carotenoids in serum requires training and careful processing. We were able to successfully 
execute the sample collection protocol with the personnel and facilities available to our 
collaborators at UASLP. This pilot study was intended to assess the feasibility of collecting the 
necessary data to successfully measure carotenoids in a large cohort of young Mexican adults. 
Although, the laboratory in the school of medicine did not have facilities with amber lighting, we 
were easily able to create a low light setting in which to collect and process the samples. Even with 
a language barrier between trainer and trainees the collection protocol was successfully taught to 
the phlebotomist and other students collection blood samples. The students from CIACyT that 
administered the tailored FFQ and took anthropometric measurements were also skilled at properly 
collecting this data accurately. By the conclusion of data collection for this pilot study, the 
procedure for gathering data and blood samples from the participants was well established with 
those that would be participating in future data collection.   
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 Similar to what was reported in previous studies there is a link between intake of carotenoid 
containing foods and the circulating levels of carotenoids (25-27). The statistical models utilized 
in this study indicate that there are many environmental and physiological factors that can affect 
the levels of carotenoids in the plasma. Although, Romieu and her team showed significant 
correlations when adjusting for age, sex, BMI, total calorie intake, TC and TG we demonstrated 
that accounting for fat intake in the diet allows for an improvement in the strength in these 
correlations (13). However, one limitation of the present study was the lack of information on the 
smoking status and history of the participants. Several studies have linked smoking to decreased 
serum antioxidants including β-carotene (28, 29). Adjusting for smoking status will be important 
moving forward to account for the physiological effect of smoking on carotenoid status. This 
variable was not addressed in our interview with the pilot participants so was not included in our 
analysis. There were no significant correlations between intakes of total carotenoids with β-
carotene in the plasma nor were there very strong correlations between intakes of the other 
carotenoids with circulating levels. The strongest correlation of intake and plasma levels was 
demonstrated by lycopene intake, which was significantly correlated with circulating levels of total 
lycopene and the isoforms measured here.  
Our results show that there are significant positive correlations between reported intakes 
of carotenoid containing foods and plasma levels of these compounds. Given the variability of 
carotenoid absorption and metabolism research has shown that intake of carotenoids is not always 
proportionately reflected in the plasma (30). However, dietary recall using a tailored FFQ is useful 
as a tool for estimating plasma levels (13). As this protocol is being implemented in the 
longitudinal arm of the UP AMIGOS study there is an opportunity to expand upon this work. The 
availability of estimated intakes from previous data collection allows for the examination of the 
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change in consumption over time and also to compare the ability of two different questionnaires 
to adequately capture intake of carotenoids in this population. Additionally, having the ability to 
measure carotenoids in serum would allow for the development and refinement of the tailored FFQ 
as a tool to estimate plasma levels of carotenoids in large populations of Mexicans living in 
Mexico. The next step will be to determine the value of this survey as a proxy for estimating serum 
concentrations of carotenoids in a larger group of individuals living in San Luis Potosi, Mexico.   
The utility of having a non-invasive, inexpensive tool for estimating plasma levels of 
carotenoids would allow for closer assessment of risk for deficiency and other health 
complications. However, as stated above, plasma carotenoid levels are under the influence of 
environmental and physiological factors that can impact the ability to predict plasma levels based 
on dietary intake. Future research should be aimed at continuing to refine non-invasive tools such 
as the tailored FFQ discussed here to give a better understanding of how dietary intake of 
carotenoids effects availability of carotenoids for body processes. The influence of carotenoids on 
overall health is wide in scope and so distinguishes this group of compounds as a crucial target for 
future nutritional interventions (3). 
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Chapter 6 
Concluding Remarks and Future Directions 
Concluding Remarks 
 According to the National health and Nutrition Survey in Mexico (ENSANUT) 2006 
49.8% of adults have metabolic syndrome (MetS) (1).  This is number far surpasses the prevalence 
of this condition in the United States. As of 2006, 34.1% of US adults had MetS (2). The rates of 
overweight and obesity in Mexico have also reached startling proportions. In that same year, over 
70% of the population were overweight or obese compared to over 73% of adults in the US (3). 
Overweight and obesity have been linked to life-threatening comorbidities and are defining 
characteristics of MetS.  
 Overweight and obesity alone have not been shown to be strong indicators for disease risk. 
Abdominal obesity has been shown to impart deleterious effects on health beyond what is observed 
in individuals who have subcutaneous adiposity in the lower extremities (4). Measuring waist 
circumference (WC) has been incorporated into definitions of MetS due to its strong association 
with metabolic disease and is a suitable measurement of visceral adiposity (5, 6). Additionally this 
measure is useful as a non-invasive, simple measure that can be applied to large populations, 
although dual-energy X-ray absorptiometry (DEXA) has been shown to be more accurate at 
predicting body composition (7). WC is also one of the most prevalent risk factors for MetS, with 
46.0% and 30.0% of American women and men, respectively, showing excess abdominal obesity 
and 83.8% and 62.9% women and men, respectively, in the Mexican population have abdominal 
obesity according to International Diabetes Federation  (IDF) criteria (1, 2). However, the cutoff 
criteria for WC is a subject of ongoing debate. There are ethnicity-specific WC cutoff points 
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established for many populations around the globe, however, those currently applied to the 
Mexican population were formulated based on a South Asian population (8).  
 The data presented in Chapter 2 of this work demonstrated that more work is needed to 
determine the best WC cutoff criteria for this population. Our findings indicate that the IDF 
criteria, which are currently used to diagnose MetS in Mexico, are less specific than the American 
Heart Association cutoff criteria. It can be argued that it is advantageous to identify those that are 
even at marginal risk to prevent disease progression. However, the IDF WC cutoffs may identify 
individuals who are not necessarily at risk for MetS and so are too broad. This is important when 
allocating limited public health resources. The goal of these interventions is to target those that are 
at the highest risk or who are already showing signs of disease.  
 The factors that contribute to the development of obesity and MetS are a complex, 
interwoven collection of factors that stem from diet, lifestyle, and genetic, physiological and 
environmental influences. Interventions target these factors, both individually and in combination, 
in an attempt to prevent the progression of and reverse the harmful effects of excess weight gain. 
Furthermore, the growth of our understanding of the genetic contribution to obesity has opened 
the door for new avenues of identifying individuals at risk. The work presented in Chapter 3 is 
focused on identifying nutrition and genetics focused strategy to prevent the progression of another 
comorbidity of obesity, dyslipidemia.  
 Examination of the effects of carotenoids on health reveals that these compounds play an 
essential role in many body processes that are vital for health (9, 10). Most relevant to our study, 
is the role of retinoic acid in lipid metabolism. The efficiency of carotenoid oxygenases, in various 
body tissues, to convert these compounds to vitamin A influences the availability of retinoic acid 
for body processes such as cell differentiation, embryogenesis and lipid metabolism (11). Our 
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findings indicate that the relationship between genotype of single nucleotide polymorphisms 
(SNPs) within the locus of β,β-carotene-15,15’-oxyegenase 1 (BCO1) are associated with changes 
in the lipid profile. This relationship becomes stronger when we account for intake of carotenoids 
in the diet. Our conclusions from the work presented in Chapter 4 may contribute to the future 
development of interventions to combat the problem of dyslipidemia in the Mexican population.  
 To move forward in characterizing the relationship between dietary intake of carotenoids 
and physiologic outcomes we examined the feasibility and prospective data that would come from 
measuring plasma carotenoids in our population. This pilot study enabled us to successfully 
establish a protocol to collect blood for the measurement of carotenoids and to help validate a 
tailored food frequency questionnaire as a tool to accurately assess intake of carotenoids and 
thereby allowing us to predict plasma levels of carotenoids. Even in our limited sample we 
observed correlations between intake of carotenoids and plasma levels showing promise for future 
studies in a larger cohort.  
 The body of this work has served to contribute pieces of the puzzle that is the link between 
genetics and nutrition in the prevention of disease and maintenance of health. Further research is 
necessary to explicitly characterize the relationship between nutrition, genetics and disease.  
Future Directions 
 The UP AMIGOS project, a collaborative endeavor between the Universities of San Luis 
Potosi and Illinois: A Multidisciplinary Investigation on Genetics, Obesity and Socio-
Environmental Factors is approaching its 8th year of exploring the contributing factors to obesity 
and health in young Mexican adults. As this project approaches the longitudinal arm of data 
collection, there are new opportunities to expand on the findings reported here.  
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 The risk factors for obesity and MetS have been found to be apparent in this population, 
with WC showing promise as an indicator for risk in this age and ethnic population. Further 
analysis using the data available now could be used to establish WC cutoffs specific to this 
population. Having population specific WC cutoffs would contribute to initiatives to identify risk 
and open opportunities for intervention. 
 There is great potential for use of the genetic data collected and reported in Chapter 3 of 
this work to be used to build a genetic risk score that includes SNPs in the BCO1 locus. Although, 
there were two SNPs reported in detail here, with the genotyping platforms available to this 
laboratory, we are able to genotype over 150 different SNPs across the genome. Exploration of the 
interaction between BCO1 and other genes that are involved in lipid metabolism would allow us 
to compile a score for increased or decreased risk for dyslipidemia, CVD or other metabolic 
disease. Providing another avenue for identifying those individuals at risk and for tailoring 
interventions to work with the genetics of the individual. However, genetics, like many other 
biological facets of life are influenced by the environment. Research has shown that the genetic 
environment that relate to ethnicity of the individual can affect gene expression (12). The increase 
in knowledge about these ancestry informative markers, can help refine the associations between 
genetics and health related phenotypes by allowing us to account for the heterogeneous genetic 
admixture that is characteristic of Mexican population (13).  
 In the future, conducting a dietary intervention trial over a period of at least one to three 
months or, ideally, longer, would allow for the detailed examination of the relationship between 
dietary intakes of carotenoids and the lipid profile. Alleles that result in low conversion of 
carotenoids by BCO1 have been identified (14). Identifying individuals that carry these low 
conversion genotypes prior to administration of supplementation with carotenoids could be 
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coupled with detailed diet recalls. Using a crossover design supplementing with preformed vitamin 
A, ProA carotenoids as well as other carotenoids would allow for explicit characterization of the 
physiological response of individuals in each group. Validation of the food frequency 
questionnaire developed for the pilot study presented in Chapter 5, as a measure of carotenoid 
intake in this region of Mexico would set the stage for accurate collection of dietary data in this 
study. The changes in plasma levels of carotenoids as well as the lipid profile could be assessed 
between the low and high converters at different time points both during and after the intervention 
as well as during washout periods. In addition, accounting for other factors such as smoking status, 
exercise and seasonality of foods would further enhance the utility of results of a study of this 
nature. Compiling this data would allow for inspection of the changes in plasma levels of 
carotenoids and lipid profile over time. This would further illuminate the association between 
BCO1 and the lipid profile. Results of a study like this could translate into the determination of 
tailored recommendations of doses of carotenoids that could help augment the positive effects of 
these compounds on health, especially on the lipid profile.  
The overall objective of this work was to contribute to the future development of 
interventions that could improve the health of populations around the globe. Great strides have 
been made in correcting deficiency of carotenoids and vitamin A but it is now our opportunity to 
discover ways to make the food we eat and the nutrients we get from it work to improve quality of 
life and correct disease processes. Nutrition is the pillar on which our health stands, without it we 
cannot maintain our health or heal our wounds. As our knowledge of the essential role that nutrition 
plays in health we can begin to focus on applying what we know to make food work with 
physiology to improve our health. Food becomes the foundation of our physical bodies and fuels 
every physiological action from birth to death. The work presented here serves to add to the 
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growing wealth of knowledge that will build the foundation for future work examining the role of 
vitamin A and carotenoids in health, as well as the importance of diet in mediating the relationship 
between genetics and health outcomes.  
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Appendix A: Reference for measurement of Waist Circumference (English)  
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Appendix B: List of covariates adjusted for by model 
 
Model Number Covariates included in the model  
1 Age, sex 
2 Age, sex, BMI 
3 Age, sex, BMI, Family history of CVD 
4 Age, sex, BMI Category 
5 Age, sex, BMI Category, Family history of CVD 
6 Age, sex, BMI (normal v. ow/ob) 
7 Age, sex, BMI Category, Sex*Genotype 
8 Age, sex, BMI (normal v. ow/ob), Sex*Genotype 
9 Age, sex, BMI Category, BMI Category *Genotype 
10 Age, sex, BMI (normal v. ow/ob), BMI (normal v. ow/ob), 
*Genotype 
*indicates interaction term 
 
Model Number Covariates included in the nutrition models 
1 Age, sex, BMI, %fat 
2 Age, sex, BMI, %fat, Total Carotenoid intake 
3 Age, sex, BMI, %fat, β-carotene intake 
4 Age, sex, BMI, %fat, α-carotene 
5 Age, sex, BMI (normal v. ow&ob), %fat, β-cryptoxanthin 
6 Age, sex, BMI (normal v. ow&ob), %fat,  
7 Age, sex, BMI, %fat, Total Carotenoid intake 
8 Age, sex, BMI (normal v. ow&ob), %fat, β-carotene intake 
9 Age, sex, BMI (normal v. ow&ob), %fat, α-carotene 
10 Age, sex, BMI (normal v. ow&ob), %fat, β-cryptoxanthin 
*indicates interaction term. 
 Abbreviations: BMI: Body mass index; %fat= percent of calories from fat. 
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Appendix C: Adjusted means of TC, LDL, and non-HDL for genotypic models 
 
Model 2 rs6564851 rs6420424 
Phenotype G/G G/T T/T A/A A/G G/G 
N (males/females) 78/98 153/202 98/94 87/118 153/175 72/78 
TC (mg/dL) 171.7(32.0) 165.9(30.9) 167.9(31.2) 171.2(31.7) 168.5(31.0) 165.1(30.4) 
LDL (mg/dL) 99.3(26.9) 94.5(25.5) 95.1(25.6) 99.3(26.8) 96.5(25.9) 93.5(25.1) 
Non-HDL (mg/dL) 121.7(30.5) 116.5(29.1) 116.9(29.1) 121.4(30.4) 118.6(29.5) 115.7(28.7) 
Values are means (SD) adjusted for age, sex, and BMI. 
 
 
 
Model 6 rs6564851 rs6420424 
Phenotype G/G G/T T/T A/A A/G G/G 
N (males/females) 78/98 153/202 98/94 87/118 153/175 72/78 
TC (mg/dL) 175.1(33.3) 168.3(32.2) 169.7(32.3) 174.3(32.7) 170.6(32.4) 167.0(31.4) 
LDL (mg/dL) 102.3(28.4) 96.7(27.0) 96.9(26.9) 102.0(28.0) 98.6(27.4) 95.6(26.3) 
Non-HDL (mg/dL) 126.4(32.7) 120.1(31.3) 120.1(31.1) 125.8(32.3) 122.0(31.8) 119.0(30.6) 
Values are means (SD) adjusted for age, sex, and BMIc. 
 
 
 
Model 6N rs6564851 rs6420424 
Phenotype G/G G/T T/T A/A A/G G/G 
N (males/females) 57/66 102/134 55/59 64/87 121/129 45/58 
TC (mg/dL) 178.3(34.3) 169.9(32.9) 166.2(32.1) 176.0(33.7) 169.9(33.3) 165.8(32.1) 
LDL (mg/dL) 104.4(28.7) 97.0(26.8) 95.1(26.2) 103.1(28.0) 97.4(27.1) 94.8(26.0) 
Non-HDL (mg/dL) 128.9(33.1) 120.9(31.2) 118.7(30.5) 127.2(32.4) 121.1(31.6) 118.2(30.4) 
Values are means (SD) adjusted for age, sex, BMIc, and %fat. 
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Model 7N rs6564851 rs6420424 
Phenotype G/G G/T T/T A/A A/G G/G 
N (males/females) 57/66 102/134 55/59 64/87 121/129 45/58 
TC (mg/dL) 179.9(34.5) 170.2(33.2) 167.6(32.3) 177.3(33.9) 170.2(33.2) 167.4(32.3) 
LDL (mg/dL) 105.7(28.9) 97.3(26.7) 96.6(26.4) 104.2(28.2) 97.8(27.0) 96.3(26.2) 
Non-HDL (mg/dL) 130.5(33.2) 121.2(31.0) 120.2(30.7) 128.4(32.5) 121.5(31.5) 119.8(30.7) 
Values are means (SD) adjusted for age, sex, BMIc, %fat, and Carotenoids. 
 
Model 8N rs6564851 rs6420424 
Phenotype G/G G/T T/T A/A A/G G/G 
N (males/females) 57/66 102/134 55/59 64/87 121/129 45/58 
TC (mg/dL) 179.3(34.5) 170.0(32.7) 167.5(32.3) 176.8(33.8) 170.1(33.3) 167.3(32.4) 
LDL (mg/dL) 105.0(28.7) 97.2(26.5) 96.5(26.4) 103.6(27.9) 97.8(26.9) 96.2(26.2) 
Non-HDL (mg/dL) 130.5(33.2) 121.2(31.0) 120.2(30.7) 127.8(32.4) 121.4(31.5) 119.8(30.7) 
Values are means (SD) adjusted for age, sex, BMIc, %fat, and BC. 
 
 
Model 9N rs6564851 rs6420424 
Phenotype G/G G/T T/T A/A A/G G/G 
N (males/females) 57/66 102/134 55/59 64/87 121/129 45/58 
TC (mg/dL) 178.4(34.6) 170.1(33.2) 169.1(32.9) 176.6(34.0) 170.1(33.5) 168.3(32.8) 
LDL (mg/dL) 104.7(28.9) 97.2(27.0) 97.8(27.0) 103.7(28.2) 97.7(27.2) 97.1(26.6) 
Non-HDL (mg/dL) 129.1(33.1) 120.9(31.2) 121.7(31.2) 127.7(32.5) 121.1(31.5) 120.9(31.1) 
Values are means (SD) adjusted for age, sex, BMIc, %fat, and AC. 
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Model 10N rs6564851 rs6420424 
Phenotype G/G G/T T/T A/A A/G G/G 
N (males/females) 57/66 102/134 55/59 64/87 121/129 45/58 
TC (mg/dL) 176.9(34.2) 169.7(33.1) 166.7(32.4) 176.0(33.4) 169.5(33.0) 166.1(31.8) 
LDL (mg/dL) 104.2(28.7) 96.5(26.8) 95.6(26.4) 103.4(27.9) 97.1(26.8) 94.9(25.8) 
Non-HDL (mg/dL) 127.6(32.8) 120.4(31.2) 119.3(30.8) 127.3(32.2) 120.6(31.2) 118.4(30.2) 
Values are means (SD) adjusted for age, sex, BMIc, %fat, and Bcryp. 
9
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Appendix D: R-square and p-value of SNP for general linear models by 
BCO1 SNPs 
 
SNP rs6564851 
MODEL 1 
ADDITIVE DOMINANT RECESSIVE 
R-square p SNP R-square p SNP R-square p SNP 
TC 0.0485 0.2300 0.0450 0.1303 0.0438 0.2006 
TG 0.0337 0.6883 0.0330 0.9908 0.0336 0.4152 
LDL 0.0393 0.1484 0.0370 0.0728 0.0347 0.1766 
VLDL 0.0337 0.6883 0.0326 0.9908 0.0336 0.4152 
HDL 0.0360 0.5077 0.0402 0.7606 0.0416 0.3452 
NON-HDL 0.0504 0.2260 0.4515 0.0984 0.0425 0.2975 
 
SNP rs6564851 
MODEL 2 
ADDITIVE DOMINANT RECESSIVE 
R-square p SNP R-square p SNP R-square p SNP 
TC 0.0958 0.1707 0.0952 0.0797 0.0907 0.9514 
TG 0.1726 0.9508 0.1725 0.9019 0.1725 0.8141 
LDL 0.0949 0.1578 0.0948 0.0568 0.0897 0.6990 
VLDL 0.1726 0.9508 0.1725 0.9019 0.1725 0.8141 
HDL 0.1276 0.7926 0.1272 0.6488 0.1270 0.7441 
NON-HDL 0.1577 0.1846 0.1576 0.0669 0.1534 0.6445 
 
SNP rs6564851 
MODEL 3 
ADDITIVE DOMINANT RECESSIVE 
R-square p SNP R-square p SNP R-square p SNP 
TC 0.0870 0.3325 0.0860 0.2064 0.0836 0.7506 
TG 0.1424 0.8061 0.1418 0.9638 0.1423 0.5263 
LDL 0.1065 0.4746 0.1065 0.2260 0.1042 0.8062 
VLDL 0.1424 0.8061 0.1418 0.9638 0.1423 0.5263 
HDL 0.1286 0.6612 0.1281 0.4786 0.1275 0.7614 
NON-HDL 0.1502 0.4610 0.1501 0.2215 0.1479 0.8573 
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SNP rs6564851 
MODEL 4 
ADDITIVE DOMINANT RECESSIVE 
R-square p SNP R-square p SNP R-square p SNP 
TC 0.0848 0.1432 0.0839 0.0705 0.0792 0.8896 
TG 0.1454 0.8530 0.1450 0.8793 0.1452 0.6444 
LDL 0.0806 0.1350 0.0804 0.0493 0.0748 0.7677 
VLDL 0.1454 0.8530 0.1450 0.8793 0.1452 0.6444 
HDL 0.1124 0.8652 0.1123 0.6547 0.8943 0.8943 
NON-HDL 0.1338 0.1535 0.1336 0.057 0.1287 0.7696 
 
 
SNP rs6564851 
MODEL 5 
ADDITIVE DOMINANT RECESSIVE 
R-square p SNP R-square p SNP R-square p SNP 
TC 0.0746 0.2835 0.0734 0.1818 0.0707 0.7115 
TG 0.1107 0.7205 0.1097 0.9716 0.1105 0.4522 
LDL 0.0874 0.4200 0.0873 0.1977 0.0846 0.8706 
VLDL 0.1107 0.7205 0.1097 0.9716 0.1106 0.4522 
HDL 0.1135 0.7384 0.1132 0.5104 0.1126 0.8617 
NON-HDL 0.1203 0.3843 0.1200 0.1854 0.1173 0.9536 
 
SNP rs6564851 
MODEL 6 
ADDITIVE DOMINANT RECESSIVE 
R-square p SNP R-square p SNP R-square p SNP 
TC 0.0709 0.1160 0.0406 0.0425 0.0642 0.7921 
TG 0.1238 0.9844 0.1238 0.8668 0.1238 0.9987 
LDL 0.0677 0.1051 0.0678 0.0339 0.0611 0.5385 
VLDL 0.1238 0.9844 0.1238 0.8668 0.1238 0.9987 
HDL 0.1054 0.7639 0.1053 0.4812 0.1046 0.9669 
NON-HDL 0.1135 0.1209 0.1135 0.0397 0.1077 0.4960 
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SNP rs6564851 
MODEL 7 
ADDITIVE DOMINANT RECESSIVE 
R-square p SNP R-square p SNP R-square p SNP 
TC 0.0850 0.9531 0.0841 0.7778 0.0793 0.7871 
TG 0.1487 0.2904 0.1450 0.9698 0.1482 0.1367 
LDL 0.0811 0.8449 0.0808 0.5873 0.0748 0.9842 
VLDL 0.1487 0.2904 0.1450 0.9698 0.1481 0.1367 
HDL 0.1160 0.2786 0.1158 0.1133 0.1129 0.4141 
NON-HDL 0.1346 0.7703 0.1338 0.7129 0.1290 0.6425 
 
SNP rs6564851 
MODEL 8 
ADDITIVE DOMINANT RECESSIVE 
R-square p SNP R-square p SNP R-square p SNP 
TC 0.0713 0.8819 0.0710 0.6444 0.0644 0.7172 
TG 0.1285 0.2026 0.1238 0.9484 0.1278 0.0977 
LDL 0.0681 0.8890 0.0681 0.6591 0.0611 0.9784 
VLDL 0.1285 0.2026 0.1238 0.9484 0.1278 0.0977 
HDL 0.1106 0.1782 0.1106 0.0622 0.1053 0.4868 
NON-HDL 0.1145 0.7270 0.1136 0.7593 0.1082 0.5587 
 
SNP rs6564851 
MODEL 9 
ADDITIVE DOMINANT RECESSIVE 
R-square p SNP R-square p SNP R-square p SNP 
TC 0.0947 0.3424 0.0883 0.3911 0.0852 0.2530 
TG 0.1502 0.7334 0.1455 0.9438 0.1495 0.3636 
LDL 0.0861 0.7224 0.0827 0.6726 0.0780 0.5395 
VLDL 0.1502 0.7334 0.1455 0.9438 0.1495 0.3636 
HDL 0.1202 0.4770 0.1156 0.4954 0.1165 0.3640 
NON-HDL 0.1392 0.7008 0.1357 0.6947 0.1325 0.4371 
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SNP rs6564851 
MODEL 10 
ADDITIVE DOMINANT RECESSIVE 
R-square p SNP R-square p SNP R-square p SNP 
TC 0.0737 0.4127 0.0730 0.2197 0.0643 0.9031 
TG 0.1240 0.9536 0.1238 0.9080 0.1239 0.8170 
LDL 0.0689 0.6942 0.0686 0.4595 0.0612 0.8636 
VLDL 0.1240 0.9536 0.1238 0.9080 0.1239 0.8170 
HDL 0.1089 0.3173 0.1071 0.2733 0.1052 0.5257 
NON-HDL 0.1141 0.8096 0.1140 0.5466 0.1077 0.9678 
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SNP rs6420424 
MODEL 1 
ADDITIVE DOMINANT RECESSIVE 
R-square p SNP R-square p SNP R-square p SNP 
TC 0.0458 0.2300 0.0448 0.1303 0.0439 0.2006 
TG 0.0337 0.6883 0.0325 0.9908 0.0336 0.4152 
LDL 0.0379 0.1484 0.0370 0.0728 0.0347 0.1766 
VLDL 0.0337 0.6883 0.0326 0.9908 0.0336 0.4152 
HDL 0.0422 0.5077 0.0402 0.7606 0.0415 0.3452 
NON-HDL 0.4554 0.2260 0.4515 0.0984 0.0425 0.2975 
 
SNP rs6420424 
MODEL 2 
ADDITIVE DOMINANT RECESSIVE 
R-square p SNP R-square p SNP R-square p SNP 
TC 0.0907 0.2195 0.0890 0.1691 0.0894 0.1392 
TG 0.1608 0.8877 0.1606 0.7676 0.1607 0.6402 
LDL 0.0940 0.1472 0.0922 0.1057 0.0921 0.1095 
VLDL 0.1608 0.8877 0.1606 0.7676 0.1607 0.6402 
HDL 0.1323 0.7884 0.1316 0.9717 0.1322 0.5278 
NON-HDL 0.1501 0.2290 0.1487 0.1539 0.1486 0.1624 
 
SNP rs6420424 
MODEL 3 
ADDITIVE DOMINANT RECESSIVE 
R-square p SNP R-square p SNP R-square p SNP 
TC 0.0844 0.3507 0.0829 0.2723 0.0835 0.2061 
TG 0.1326 0.7942 0.1326 0.5109 0.1321 0.6982 
LDL 0.1055 0.3421 0.1043 0.2269 0.1043 0.2308 
VLDL 0.1326 0.7942 0.1326 0.5109 0.1321 0.6982 
HDL 0.1361 0.7690 0.1354 0.7308 0.1361 0.4723 
NON-HDL 0.1431 0.4331 0.1420 0.3149 0.1424 0.2649 
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SNP rs6420424 
MODEL 4 
ADDITIVE DOMINANT RECESSIVE 
R-square p SNP R-square p SNP R-square p SNP 
TC 0.0791 0.1948 0.0775 0.1307 0.0773 0.1469 
TG 0.1327 0.7774 0.1320 0.8507 0.1327 0.4793 
LDL 0.0781 0.1266 0.0765 0.0775 0.0754 0.1194 
VLDL 0.1327 0.7774 0.1320 0.8507 0.1327 0.4793 
HDL 0.1132 0.6350 0.1119 0.9302 0.1129 0.3907 
NON-HDL 0.1236 0.2093 0.1227 0.1127 0.1214 0.1992 
 
SNP rs6420424 
MODEL 5 
ADDITIVE DOMINANT RECESSIVE 
R-square p SNP R-square p SNP R-square p SNP 
TC 0.0732 0.2848 0.0717 0.2045 0.0719 0.1852 
TG 0.0992 0.8267 0.0990 0.6212 0.0991 0.6052 
LDL 0.0865 0.2790 0.0855 0.1641 0.0847 0.2236 
VLDL 0.0992 0.8267 0.0990 0.6212 0.0991 0.6052 
HDL 0.1157 0.6564 0.1144 0.7876 0.1157 0.3595 
NON-HDL 0.1121 0.3676 0.1112 0.2235 0.1108 0.2727 
 
SNP rs6420424 
MODEL 6 
ADDITIVE DOMINANT RECESSIVE 
R-square p SNP R-square p SNP R-square p SNP 
TC 0.0695 0.1392 0.0676 0.0970 0.0672 0.1090 
TG 0.1131 0.9279 0.1128 0.9780 0.1130 0.7251 
LDL 0.0663 0.1202 0.0643 0.0796 0.0636 0.1027 
VLDL 0.1131 0.9279 0.1128 0.9780 0.1130 0.7251 
HDL 0.1031 0.6001 0.1015 0.7910 0.1030 0.3145 
NON-HDL 0.1059 0.1735 0.1046 0.1022 0.1036 0.1516 
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SNP rs6420424 
MODEL 7 
ADDITIVE DOMINANT RECESSIVE 
R-square p SNP R-square p SNP R-square p SNP 
TC 0.0794 0.8999 0.0778 0.6901 0.0775 0.7238 
TG 0.1335 0.7585 0.1322 0.7046 0.1334 0.4620 
LDL 0.0785 0.8927 0.0768 0.6571 0.0754 0.9288 
VLDL 0.1335 0.7585 0.1322 0.7046 0.1334 0.4620 
HDL 0.1164 0.3388 0.1150 0.1445 0.1133 0.5976 
NON-HDL 0.1240 0.8952 0.1227 0.9216 0.1217 0.6590 
 
SNP rs6420424 
MODEL 8 
ADDITIVE DOMINANT RECESSIVE 
R-square p SNP R-square p SNP R-square p SNP 
TC 0.0707 0.6911 0.0685 0.4462 0.0679 0.5286 
TG 0.1144 0.6601 0.1134 0.5558 0.1142 0.3882 
LDL 0.0667 0.8841 0.0644 0.8324 0.0639 0.7110 
VLDL 0.1144 0.6601 0.1134 0.5558 0.1142 0.3882 
HDL 0.1079 0.2191 0.1063 0.0851 0.1033 0.6849 
NON-HDL 0.1069 0.7545 0.1046 0.8741 0.1045 0.4472 
 
SNP rs6420424 
MODEL 9 
ADDITIVE DOMINANT RECESSIVE 
R-square p SNP R-square p SNP R-square p SNP 
TC 0.0859 0.6128 0.0789 0.8224 0.0838 0.2385 
TG 0.1415 0.4007 0.1341 0.6863 0.1401 0.1535 
LDL 0.0796 0.9874 0.0766 0.9976 0.0768 0.8247 
VLDL 0.1415 0.4007 0.1341 0.6863 0.1401 0.1535 
HDL 0.1242 0.2852 0.1177 0.2640 0.1211 0.1369 
NON-HDL 0.1265 0.9294 0.1230 0.9765 0.1241 0.6206 
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SNP rs6420424 
MODEL 10 
ADDITIVE DOMINANT RECESSIVE 
R-square p SNP R-square p SNP R-square p SNP 
TC 0.0701 0.8510 0.0676 0.9851 0.0677 0.6058 
TG 0.1141 0.7271 0.1133 0.5928 0.1139 0.4583 
LDL 0.0664 0.9772 0.0643 0.9724 0.0637 0.8128 
VLDL 0.1141 0.7271 0.1133 0.5928 0.1139 0.4583 
HDL 0.1068 0.3131 0.1021 0.5510 0.1068 0.1267 
NON-HDL 0.1059 0.9958 0.1046 0.9259 0.1036 0.9879 
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Appendix E: R-square and p-value of SNP for general linear models 
including nutrition variables by BCO1 SNPs 
 
SNP rs6420424 
MODEL 1 
ADDITIVE DOMINANT RECESSIVE 
R-square p SNP R-square p SNP R-square p SNP 
TC 0.1052 0.1154 0.1027 0.0781 0.1018 0.1025 
TG 0.1697 0.9924 0.1697 0.9115 0.1697 0.9300 
LDL 0.1076 0.0788 0.1058 0.0407 0.1024 0.1124 
VLDL 0.1697 0.9924 0.1697 0.9115 0.1697 0.9300 
HDL 0.1265 0.4845 0.1241 0.6503 0.1252 0.3734 
NON-HDL 0.1663 0.1129 0.1646 0.0642 0.1625 0.1227 
 
SNP rs6420424 
MODEL 2 
ADDITIVE DOMINANT RECESSIVE 
R-square p SNP R-square p SNP R-square p SNP 
TC 0.1104 0.1547 0.1089 0.0829 0.1067 0.1662 
TG 0.1791 0.9630 0.1789 0.9951 0.1791 0.7942 
LDL 0.1148 0.1080 0.1139 0.0444 0.1090 0.1986 
VLDL 0.1791 0.9630 0.1789 0.9951 0.1791 0.7942 
HDL 0.1258 0.3987 0.1227 0.5848 0.1240 0.3275 
NON-HDL 0.1750 0.1504 0.1743 0.0655 0.1706 0.2232 
 
SNP rs6420424 
MODEL 3 
ADDITIVE DOMINANT RECESSIVE 
R-square p SNP R-square p SNP R-square p SNP 
TC 0.1094 0.2366 0.1084 0.1223 0.10636 0.2376 
TG 0.1809 0.9598 0.1808 0.9778 0.1809 0.7953 
LDL 0.1119 0.1765 0.1113 0.0754 0.1073 0.2603 
VLDL 0.1809 0.9598 0.1808 0.9778 0.1809 0.7953 
HDL 0.1247 0.4958 0.1224 0.5885 0.1231 0.4206 
NON-HDL 0.1739 0.2193 0.1733 0.0983 0.1703 0.2810 
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SNP rs6420424 
MODEL 4 
ADDITIVE DOMINANT RECESSIVE 
R-square p SNP R-square p SNP R-square p SNP 
TC 0.1020 0.2611 0.1015 0.1178 0.0982 0.3285 
TG 0.1795 0.8202 0.1788 0.9082 0.1795 0.5334 
LDL 0.1075 0.1807 0.1072 0.0683 0.1018 0.3637 
VLDL 0.1795 0.8202 0.1788 0.9082 0.1795 0.5334 
HDL 0.1211 0.4327 0.1179 0.6350 0.1195 0.3293 
NON-HDL 0.1661 0.2588 0.1660 0.1039 0.1618 0.4379 
 
SNP rs6420424 
MODEL 5 
ADDITIVE DOMINANT RECESSIVE 
R-square p SNP R-square p SNP R-square p SNP 
TC 0.1028 0.1452 0.1010 0.0817 0.0990 0.1478 
TG 0.1725 0.9850 0.1724 0.9269 0.1724 0.8649 
LDL 0.1068 0.0787 0.1054 0.0344 0.1004 0.1436 
VLDL 0.1725 0.9850 0.1724 0.9269 0.1724 0.8649 
HDL 0.1301 0.4952 0.1279 0.5329 0.1282 0.4657 
NON-HDL 0.1665 0.1238 0.1652 0.0589 0.1619 0.1665 
 
SNP rs6420424 
MODEL 6 
ADDITIVE DOMINANT RECESSIVE 
R-square p SNP R-square p SNP R-square p SNP 
TC 0.0775 0.0710 0.0751 0.0397 0.0717 0.0961 
TG 0.1184 0.9509 0.1182 0.8478 0.1182 0.8628 
LDL 0.0750 0.0632 0.0735 0.0276 0.0676 0.1281 
VLDL 0.1184 0.9509 0.1182 0.8478 0.1182 0.8628 
HDL 0.1081 0.3691 0.1038 0.8138 0.1070 0.2203 
NON-HDL 0.1135 0.0915 0.1123 0.0400 0.1073 0.1587 
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SNP rs6420424 
MODEL 7 
ADDITIVE DOMINANT RECESSIVE 
R-square p SNP R-square p SNP R-square p SNP 
TC 0.0825 0.0706 0.0813 0.0281 0.0746 0.1669 
TG 0.1343 0.9097 0.1341 0.7988 0.1341 0.8042 
LDL 0.0815 0.0661 0.0810 0.0224 0.0721 0.2260 
VLDL 0.1343 0.9097 0.1341 0.7988 0.1341 0.8042 
HDL 0.1128 0.4134 0.1089 0.8774 0.1120 0.2340 
NON-HDL 0.1248 0.0948 0.1244 0.0331 0.1170 0.2673 
 
SNP rs6420424 
MODEL 8 
ADDITIVE DOMINANT RECESSIVE 
R-square p SNP R-square p SNP R-square p SNP 
TC 0.0792 0.0953 0.0781 0.0399 0.0724 0.1822 
TG 0.1315 0.8976 0.1312 0.7833 0.1312 0.7932 
LDL 0.0771 0.0985 0.0766 0.0359 0.0693 0.2451 
VLDL 0.1315 0.8976 0.1312 0.7833 0.1312 0.7932 
HDL 0.1108 0.4159 0.1069 0.9042 0.1101 0.2297 
NON-HDL 0.1200 0.1284 0.1196 0.0474 0.1132 0.2893 
 
SNP rs6420424 
MODEL 9 
ADDITIVE DOMINANT RECESSIVE 
R-square p SNP R-square p SNP R-square p SNP 
TC 0.0712 0.1536 0.0707 0.0591 0.0646 0.3053 
TG 0.1261 0.7812 0.1251 0.9021 0.1259 0.5393 
LDL 0.0725 0.1276 0.0725 0.0430 0.0640 0.4088 
VLDL 0.1262 0.7812 0.1251 0.9021 0.1259 0.5393 
HDL 0.1081 0.3077 0.1027 0.7894 0.1067 0.1813 
NON-HDL 0.1133 0.1748 0.1132 0.0617 0.1061 0.5052 
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SNP rs6420424 
MODEL 10 
ADDITIVE DOMINANT RECESSIVE 
R-square p SNP R-square p SNP R-square p SNP 
TC 0.0748 0.0810 0.0731 0.0380 0.0682 0.1323 
TG 0.1252 0.9400 0.1250 0.8648 0.1251 0.8170 
LDL 0.0725 0.0529 0.0714 0.0197 0.0631 0.1543 
VLDL 0.1252 0.9400 0.1250 0.8648 0.1251 0.8170 
HDL 0.1102 0.4153 0.1065 0.6862 0.1086 0.2965 
NON-HDL 0.1127 0.0873 0.1119 0.0331 0.1052 0.1997 
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SNP rs6564851 
MODEL 1 
ADDITIVE DOMINANT RECESSIVE 
R-square p SNP R-square p SNP R-square p SNP 
TC 0.1163 0.0783 0.1152 0.0327 0.1095 0.1662 
TG 0.1995 0.8481 0.1989 0.9353 0.1994 0.6093 
LDL 0.1146 0.0697 0.1142 0.0236 0.1059 0.2456 
VLDL 0.1995 0.8481 0.1989 0.9353 0.1994 0.6093 
HDL 0.1273 0.9108 0.1269 0.9820 0.1273 0.6775 
NON-HDL 0.1833 0.0947 0.1828 0.0345 0.1765 0.2495 
 
SNP rs6564851 
MODEL 2 
ADDITIVE DOMINANT RECESSIVE 
R-square p SNP R-square p SNP R-square p SNP 
TC 0.12464 0.0819 0.1242 0.0286 0.1166 0.2515 
TG 0.2120 0.7465 0.2101 0.7366 0.2104 0.5883 
LDL 0.1231 0.0764 0.1231 0.0234 0.1132 0.4159 
VLDL 0.2110 0.7465 0.2100 0.7366 0.2104 0.5883 
HDL 0.1253 0.8686 0.1247 0.9305 0.1252 0.6399 
NON-HDL 0.1959 0.0879 0.1959 0.0277 0.1876 0.4023 
 
SNP rs6564851 
MODEL 3 
ADDITIVE DOMINANT RECESSIVE 
R-square p SNP R-square p SNP R-square p SNP 
TC 0.1256 0.1177 0.1254 0.0400 0.1179 0.3662 
TG 0.2140 0.7049 0.2130 0.6567 0.2132 0.5974 
LDL 0.1225 0.1205 0.1225 0.0396 0.1139 0.5484 
VLDL 0.2140 0.7049 0.2130 0.6567 0.2132 0.5974 
HDL 0.1226 0.9550 0.1224 0.9599 0.1225 0.7889 
NON-HDL 0.1969 0.1201 0.1970 0.0394 0.1892 0.5081 
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SNP rs6564851 
MODEL 4 
ADDITIVE DOMINANT RECESSIVE 
R-square p SNP R-square p SNP R-square p SNP 
TC 0.1115 0.2076 0.1115 0.0760 0.1049 0.5869 
TG 0.2182 0.4988 0.2153 0.9614 0.2179 0.2569 
LDL 0.1105 0.1541 0.1103 0.0566 0.1020 0.7793 
VLDL 0.2182 0.4988 0.2153 0.9614 0.2179 0.2569 
HDL 0.1206 0.9057 0.1201 0.9678 0.1205 0.6831 
NON-HDL 0.1834 0.1955 0.1831 0.0778 0.1764 0.8635 
 
SNP rs6564851 
MODEL 5 
ADDITIVE DOMINANT RECESSIVE 
R-square p SNP R-square p SNP R-square p SNP 
TC 0.1090 0.1901 0.1085 0.0785 0.1038 0.3014 
TG 0.2043 0.6336 0.2031 0.5851 0.2042 0.3568 
LDL 0.1109 0.0893 0.1109 0.0281 0.1014 0.3999 
VLDL 0.2043 0.6336 0.2031 0.5851 0.2042 0.3568 
HDL 0.1265 0.8608 0.1258 0.9241 0.1263 0.6331 
NON-HDL 0.1787 0.2011 0.1787 0.0744 0.1731 0.4586 
 
SNP rs6564851 
MODEL 6 
ADDITIVE DOMINANT RECESSIVE 
R-square p SNP R-square p SNP R-square p SNP 
TC 0.0909 0.0311 0.0887 0.0142 0.0812 0.0890 
TG 0.1423 0.8764 0.1418 0.8456 0.1421 0.6992 
LDL 0.0860 0.0393 0.0852 0.0134 0.0748 0.1741 
VLDL 0.1423 0.8764 0.1418 0.8456 0.1421 0.6992 
HDL 0.1098 0.7835 0.1088 0.7803 0.1098 0.4859 
NON-HDL 0.1345 0.0557 0.1337 0.0197 0.1251 0.1932 
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SNP rs6564851 
MODEL 7 
ADDITIVE DOMINANT RECESSIVE 
R-square p SNP R-square p SNP R-square p SNP 
TC 0.0998 0.0241 0.0988 0.0081 0.0869 0.1409 
TG 0.1635 0.8041 0.1630 0.6481 0.1628 0.7600 
LDL 0.0953 0.0328 0.0951 0.0092 0.0809 0.2969 
VLDL 0.1635 0.8041 0.1630 0.6481 0.1628 0.7602 
HDL 0.1139 0.8274 0.1132 0.8028 0.1139 0.5396 
NON-HDL 0.1513 0.0402 0.1511 0.0116 0.1389 0.2916 
 
SNP rs6564851 
MODEL 8 
ADDITIVE DOMINANT RECESSIVE 
R-square p SNP R-square p SNP R-square p SNP 
TC 0.0966 0.0342 0.0957 0.0116 0.0847 0.1647 
TG 0.1604 0.7893 0.1598 0.6186 0.1595 0.7713 
LDL 0.0914 0.0533 0.0914 0.0157 0.0789 0.3454 
VLDL 0.1604 0.7893 0.1598 0.6186 0.1595 0.7713 
HDL 0.1102 0.8266 0.1096 0.7396 0.1102 0.5489 
NON-HDL 0.1464 0.0578 0.1463 0.0175 0.1352 0.3283 
 
SNP rs6564851 
MODEL 9 
ADDITIVE DOMINANT RECESSIVE 
R-square p SNP R-square p SNP R-square p SNP 
TC 0.0003 0.1028 0.0831 0.0340 0.0736 0.3679 
TG 0.1564 0.6752 0.1546 0.9281 0.1561 0.4186 
LDL 0.0824 0.0950 0.0823 0.0303 0.0708 0.5958 
VLDL 0.1564 0.6752 0.1546 0.9281 0.1561 0.4186 
HDL 0.1064 0.8452 0.1056 0.8808 0.1064 0.5622 
NON-HDL 0.1361 0.1208 0.1360 0.0407 0.1262 0.6609 
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SNP rs6564851 
MODEL 10 
ADDITIVE DOMINANT RECESSIVE 
R-square p SNP R-square p SNP R-square p SNP 
TC 0.0793 0.0948 0.0780 0.0407 0.0719 0.1757 
TG 0.1494 0.7047 0.1484 0.6088 0.1493 0.4272 
LDL 0.0772 0.0550 0.0770 0.0167 0.0649 0.2978 
VLDL 0.1494 0.7047 0.1484 0.6088 0.1493 0.4272 
HDL 0.1113 0.7432 0.1099 0.8474 0.1113 0.4423 
NON-HDL 0.1239 0.1423 0.1237 0.0503 0.1163 0.3719 
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Appendix F: UP AMIGOS Food-Frequency Questionnaire tailored for assessment of carotenoid 
intake (Spanish Version) 
 
CUESTIONARIO DE ALIMENTACION (FRECUENCIA DE CONSUMO).  
Adaptado del Instituto Nacional de Salud Pública. Centro de Investigación en Salud Pública. 
 
Por favor indique con una cruz en la columna que corresponda a la opción más cercana a su realidad y en la columna de la derecha registre el 
número correspondiente a la frecuencia de consumo reportada. 
 
FRECUENCIA DE CONSUMO 
ALIMENTO 
Productos lácteos 
NUNCA 
MENOS DE 
UNA VEZ 
AL MES 
VECES AL 
MES 
VECES A LA 
SEMANA 
VECES Al DIA 
Observaciones 
(01) (02) 
1-3 
(03) 
1 
(04) 
2-4 
(05) 
5-6 
(06) 
1 
(07) 
2-3 
(08) 
4-5 
(09) 
6 
(10) 
1 Un vaso de leche (% grasa____) [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
2 
½ taza de queso cottage (% 
grasa____) 
[___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
3 Una rebanada de queso Oaxaca [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
4 
Una rebanada de queso Manchego 
o Chihuahua 
[___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
5 Una rebanada de queso fresco [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
6 Una cucharada de queso crema [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
7 
Una taza de yogurt o búlgaros 
(%grasso____) 
[___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
8 Un barquillo helado de leche [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
 
 
 
 
 
 
1
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Durante el año previo a este día ¿Con que frecuencia consumió usted FRUTAS? Por favor indique con una cruz, en la columna de frecuencias, la 
opción que considere más cercana a su realidad. Incluya las frutas que estuvieron disponibles solo en temporada. 
 
 
FRECUENCIA DE CONSUMO 
ALIMENTO 
Frutas 
NUNCA MENOS DE 
UNA VEZ AL 
MES 
VECES 
AL MES 
VECES A LA 
SEMANA 
VECES Al DIA 
Observaciones 
(01) (02) 
1-3 
(03) 
1 
(04) 
2-4 
(05) 
5-6 
(06) 
1 
(07) 
2-3 
(08) 
4-5 
(09) 
6 
(10) 
9 Un plátano [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
10 Un plátano macho [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
11 Una naranja [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
12 Un vaso con jugo de naranja o 
toronja 
[___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
13 Una rebanada de melón [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
14 Una manzana fresca [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
15 Una rebanada de sandia [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
16 Una rebanada de piña [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
17 Una rebanada de papaya [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
18 Una pera [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
19 Un mango [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
20 Una  mandarina [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
21 Una porción de fresas (~10) [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
22 Un durazno, chabacano o 
nectarina 
[___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
23 Una porción de uvas (de 10 a 15) [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
24 Una tuna (color: 
_______________) 
[___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
 25 Una porción de ciruelas (~6) [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
 26 Una rebanada de mamey [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
 27 Un zapote [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
 
1
1
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Durante el año previo a este día ¿Con que frecuencia consumió usted CARNES, HUEVO Y EMBUTIDOS? Por favor indique con una cruz, en la 
columna de frecuencias, la opción que considere más cercana a su realidad.  
FRECUENCIA DE CONSUMO 
ALIMENTO 
Carnes, huevo y embutidos 
NUNCA MENOS DE 
UNA VEZ AL 
MES 
VECES 
AL MES 
VECES A LA 
SEMANA 
VECES Al DIA 
Observaciones 
(01) (02) 
1-3 
(03) 
1 
(04) 
2-4 
(05) 
5-6 
(06) 
1 
(07) 
2-3 
(08) 
4-5 
(09) 
6 
(10) 
28 Un huevo de gallina [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
29 Una pieza de pollo [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
30 Una rebanada de jamón [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
31 Un plato de carne de res [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
32 Un plato de carne de cerdo [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
33 Una porción de atún (en aceite, 
agua, o salsa?) 
[___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
34 Un pedazo de chicharrón [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
35 Una salchicha [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
36 Una rebanada de tocino [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
37 Un bistec de hígado o hígados de 
pollo 
[___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
38 Un trozo de chorizo o longaniza [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
39 
Un plato de carne de pescado 
fresco (i.e. mojarra) 
[___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
40 Un plato de sardinas en tomate [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
41 Media taza de mariscos [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
42 Un plato de carnitas [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
43 Un plato de barbacoa (carne de 
res) 
[___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
44 Un plato de barbacoa (cordero) [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
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Durante el año previo a este día ¿Con que frecuencia consumió usted VERDURAS? Por favor indique con una cruz, en la columna de frecuencias, 
la opción que considere más cercana a su realidad.  
FRECUENCIA DE CONSUMO 
ALIMENTO 
Verduras 
NUNCA MENOS 
DE UNA 
VEZ AL 
MES 
VECES 
AL 
MES 
VECES A LA 
SEMANA 
VECES Al DIA MÉTODO DE COCCIÓN 
Observa-
ciones 
CRUDO 
EN 
AGUA 
EN 
ACEITE 
ASADO 
(01) (02) 
1-3 
(03) 
1 
(04) 
2-4 
(05) 
5-6 
(06) 
1 
(07) 
2-3 
(08) 
4-5 
(09) 
6 
(10) (A) (B) (C) (D) 
45 Un jitomate en salsa o guisado [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
46 Un jitomate crudo o en ensalada [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
47 Una papa  [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
48 Una Camote (naranja) [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
49 Media taza de zanahoria [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
50 Una hoja de lechuga [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
51 
Media taza de espinacas u otra 
verdura de hoja verde (acelgas) 
[___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] 
 
52 
Media taza de calabacitas o 
chayotes 
[___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] 
 
53 Media taza de nopalitos [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
54 
Chiles jalapeño o verdes 
enlatados 
[___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] 
 
55 Un plato de chiles picantes secos [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
56 
Un plato de sopa/crema de 
verduras 
[___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] 
 
57 Medio aguacate [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
58 Media taza de flor de calabaza [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
59 Media taza de coliflor [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
60 Media taza de ejotes [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
61 
Una cucharadita de salsa picante 
o chiles con sus alimentos 
[___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] 
 
62 Un platillo con chile seco [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
63 Un elote [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
64 Un plato de calabaza (naranja) [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
1
1
8
 
 
 
 
119 
 
Durante el año previo a este día ¿Con que frecuencia consumió usted LEGUMINOSAS o CEREALES? Por favor indique con una cruz, en la columna 
de frecuencias, la opción que considere más cercana a su realidad.  
FRECUENCIA DE CONSUMO 
ALIMENTO 
Leguminosas 
NUNCA MENOS 
DE UNA 
VEZ AL 
MES 
VECES AL 
MES 
VECES A LA 
SEMANA 
VECES Al DIA 
Observaciones 
(01) (02) 
1-3 
(03) 
1 
(04) 
2-4 
(05) 
5-6 
(06) 
1 
(07) 
2-3 
(08) 
4-5 
(09) 
6 
(10) 
 
65 Un plato de frijoles [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
66 Media taza de chicharos [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
67 Un plato de habas verdes [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
68 Un plato de habas secas [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
69 Un plato de lentejas o garbanzos [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
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FRECUENCIA DE CONSUMO 
ALIMENTO 
Cereales 
NUNCA MENOS 
DE UNA 
VEZ AL 
MES 
VECES 
AL MES 
VECES A LA 
SEMANA 
VECES Al DIA 
Observaciones 
(01) (02) 
1-3 
(03) 
1 
(04) 
2-4 
(05) 
5-6 
(06) 
1 
(07) 
2-3 
(08) 
4-5 
(09) 
6 
(10) 
 
70 Una tortilla de maíz [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
71 Una tortilla de trigo (tortilla de 
harina) 
[___] [___] [___] [___] [___] [___] [___] [___] [___] [___] 
 
72 Una rebanada de pan de caja (tipo 
Bimbo) 
[___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
73 Una rebanada de pan de caja 
integral 
[___] [___] [___] [___] [___] [___] [___] [___] [___] [___] 
 
74 Un bolillo o telera [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
75 Una pieza de pan de dulce [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
76 Un plato de arroz [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
77 Un plato de sopa de pasta [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
78 Un plato de avena [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
79 Un tazón de cereal de caja (tipo 
hojuelas de maíz) ¿Qué 
tipo?_______ 
[___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
80 Cereal alto en fibra ¿Cuál? 
_______ 
[___] [___] [___] [___] [___] [___] [___] [___] [___] [___] 
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Durante el año previo a este día ¿Con que frecuencia consumió usted GOLOSINAS o POSTRES? Por favor indique con una cruz, en la columna de 
frecuencias, la opción que considere más cercana a su realidad.  
FRECUENCIA DE CONSUMO 
ALIMENTO 
Golosinas o postres 
NUNCA MENOS DE 
UNA VEZ AL 
MES 
VECES 
AL 
MES 
VECES A LA SEMANA VECES Al DIA 
Observaciones 
(01) (02) 
1-3 
(03) 
1 
(04) 
2-4 
(05) 
5-6 
(06) 
1 
(07) 
2-3 
(08) 
4-5 
(09) 
6 
(10) 
 
81 Una rebanada de pastel [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
82 Una cucharadita de ate, miel, 
mermelada, cajeta o leche 
condensada 
[___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
83 Una cucharadita de chocolate en 
polvo 
[___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
84 Una tablilla/barra de chocolate [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
85 Una bolsa de frituras [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
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Durante el año previo a este día ¿Con que frecuencia consumió usted las siguientes BEBIDAS? Por favor indique con una cruz, en la columna de 
frecuencias, la opción que considere más cercana a su realidad.  
FRECUENCIA DE CONSUMO 
ALIMENTO 
Bebidas 
NUNCA MENOS DE 
UNA VEZ AL 
MES 
VECES 
AL MES 
VECES A LA 
SEMANA 
VECES Al DIA 
Observaciones 
(01) (02) 
1-3 
(03) 
1 
(04) 
2-4 
(05) 
5-6 
(06) 
1 
(07) 
2-3 
(08) 
4-5 
(09) 
6 
(10) 
 
87 Un refresco de cola mediano [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
88 Un refresco gaseoso de sabor [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
89 Un refresco dietético [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
90 Un vaso con agua de sabor 
azucarada 
[___] [___] [___] [___] [___] [___] [___] [___] [___] [___] 
 
91 Una taza de café sin azúcar [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
92 Una taza de café con azúcar [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
93 Una taza de atole sin leche [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
94 Una taza de atole con leche [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
95 Una cerveza [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
96 Una copa de vino de mesa [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
97 Una bebida con ron, brandy o 
tequila  
[___] [___] [___] [___] [___] [___] [___] [___] [___] [___] 
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Durante el año previo a este día ¿Con que frecuencia consumió usted GRASAS y qué tipo de ACEITE utiliza para cocinar? Por favor indique con 
una cruz, en la columna de frecuencias, la opción que considere más cercana a su realidad.  
FRECUENCIA DE CONSUMO 
ALIMENTO 
Aceites y grasas 
NUNCA MENOS DE 
UNA VEZ AL 
MES 
VECES 
AL MES 
VECES A LA 
SEMANA 
VECES Al DIA 
Observaciones 
(01) (02) 
1-3 
(03) 
1 
(04) 
2-4 
(05) 
5-6 
(06) 
1 
(07) 
2-3 
(08) 
4-5 
(09) 
6 
(10) 
 
98 Aceite de maíz [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
99 Aceite de soya [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
100 Aceite de girasol [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
101 Aceite de cártamo [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
102 Aceite de oliva [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
103 Una cucharadita de margarina [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
104 Una cucharadita de mantequilla [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
105 Una cucharadita de crema [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
106 Una cucharadita de mayonesa [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
107 Una cucharadita de manteca 
vegetal 
[___] [___] [___] [___] [___] [___] [___] [___] [___] [___] 
 
108 Una cucharadita de manteca 
animal 
[___] [___] [___] [___] [___] [___] [___] [___] [___] [___] 
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Durante el año previo a este día ¿Con que frecuencia consumió usted los ANTOJITOS MEXICANOS que se enlistan a continuación? Por favor 
indique con una cruz, en la columna de frecuencias, la opción que considere más cercana a su realidad.  
FRECUENCIA DE CONSUMO 
ALIMENTO 
Antojitos 
NUNCA MENOS DE 
UNA VEZ AL 
MES 
VECES 
AL MES 
VECES A LA 
SEMANA 
VECES Al DIA 
Observaciones 
(01) (02) 
1-3 
(03) 
1 
(04) 
2-4 
(05) 
5-6 
(06) 
1 
(07) 
2-3 
(08) 
4-5 
(09) 
6 
(10) 
 
109 Un taco al pastor [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
110 Un sope o quesadilla [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
111 Un plato con pozole [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
112 Un tamal [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
 
 
 
Por favor, indique cualquier otro alimento que usted consumió al menos una vez por semana y que no encontró en los alimentos anteriores, 
además de la siguiente lista, al año previo a este día. Por favor indique con una cruz, en la columna de frecuencias, la opción que considere más 
cercana a su realidad.  
FRECUENCIA DE CONSUMO 
ALIMENTO 
Otros no enumerados  
VECES A LA SEMANA VECES Al DIA Observaciones 
1 
(04) 
2-4 
(05) 
5-6 
(06) 
1 
(07) 
2-3 
(08) 
4-5 
(09) 
6 
(10) 
 
  [___] [___] [___] [___] [___] [___] [___]  
  [___] [___] [___] [___] [___] [___] [___]  
  [___] [___] [___] [___] [___] [___] [___]  
  [___] [___] [___] [___] [___] [___] [___]  
  [___] [___] [___] [___] [___] [___] [___]  
  [___] [___] [___] [___] [___] [___] [___]  
  [___] [___] [___] [___] [___] [___] [___]  
  [___] [___] [___] [___] [___] [___] [___]  
  [___] [___] [___] [___] [___] [___] [___]  
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OTRAS PREGUNTAS 
 Observaciones 
 ¿Cuántas cucharaditas de azúcar le agrega usted a su alimentos al o largo del día? Tome en cuenta lo 
que le pone al café, licuado, otras bebidas, etc. Cucharaditas  
 ¿Le agrega usted sal a sus alimentos antes de probarlos? a) Si b) No  
 ¿Se come usted el pellejo del pollo? a) Si b) No  
 ¿Se come usted el “gordito” de la carne? a) Si b) No  
  0 1-2 3-4 5-6 7-8 9-10 11-12  
 ¿Cuántos meses del año pasado consumió usted vitaminas? a b c d e f g  
 ¿Cuál o cuáles? ________________________________________________________________________________ 
  0 1-2 3-4 5-6 7-8 9-10 11-12  
 ¿Cuántos meses del año pasado consumió usted suplemento de calcio? a b c d e f g  
 ¿Cuál o cuáles? ________________________________________________________________________________ 
 ¿Considera usted que su alimentación ha cambiado durante el ultimo año? a) Si b) No  
 Si ha cambiado ¿Por qué? 
___________________________________________________________________________________________________________
__________________________________________________________________________________________________________ 
__________________________________________________________________________________________________________ 
 Observaciones 
____________________________________________________________________________________________________________________ 
____________________________________________________________________________________________________________________ 
____________________________________________________________________________________________________________________ 
Este es el final de este cuestionario, gracias por su participación. 
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Appendix G: UP AMIGOS Food-Frequency Questionnaire tailored for assessment of carotenoid 
intake (English Version) 
FOOD QUESTIONNAIRE (FRQUENCY OF CONSUMPTION) 
Please indicate with a cross in the column that corresponds to the option closest to your reality and in the right column record the 
number corresponding to the frequency of consumption reported. 
FREQUENCY OF CONSUMPTION 
FOOD 
Dairy products 
NEVER 
LESS 
THAN 
ONCE A 
MONTH 
TIMES A 
MONTH 
TIMES A WEEK TIMES A DAY 
Observations 
(01) (02) 
1-3 
(03) 
1 
(04) 
2-4 
(05) 
5-6 
(06) 
1 
(07) 
2-3 
(08) 
4-5 
(09) 
6 
(10) 
1  A glass of whole milk (%Fat____) [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
2 
 A slice of cheese or  ½ cup cottage 
cheese(%Fat____) 
[___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
3 A slice of Oaxaca cheese [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
4 
 A slice of Manchego cheese or 
Chihuahua cheese 
[___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
5 A slice of fresh cheese [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
6 A spoonful of cream cheese [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
7 
A cup of Yogurt or 
Bulgarians(%Fat____) 
[___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
8  A milk ice cream cone [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
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During the year prior to this day, how often do you consumed fruit? Please indicate with a cross in the column of frequencies, 
consider the option that is closest to reality. Include fruits that were available only in season. 
 
 
FRECUENCIA DE CONSUMO 
FOOD 
NEVER 
LESS THAN 
ONCE A 
MONTH 
TIMES A 
MONTH 
TIMES A WEEK TIMES A DAY 
Observations 
(01) (02) 1-3 1 2-4    1-3 1 
9 A banana [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
10 A Plantain [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
11 An Orange [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
12 
A glass of orange juice or 
grapefruits 
[___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
13 A slice of melon [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
14 A fresh apple [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
15 A slice of Watermelon [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
16 A slice of pineapple [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
17 A slice of papaya [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
18 A pear [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
19 A mango [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
20 A tangerine [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
21 One serving of strawberries (~10) [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
22 A peach, apricot or nectarine [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
23 One serving of grapes (10 to 15) [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
24 A prickly pear (color:______) [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
25 A plum portion (~ 6) [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
26 A slice of mamey sapote [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
27 A Zapote [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
 
 
 
 
1
2
7
 
 
 
 
128 
 
During the year prior to this day, how often do you consume MEATS, SAUSAGES AND EGG? Please indicate with a cross in the 
column of frequencies, consider the option that is closest to reality.  
FREQUENCY OF CONSUMPTION 
Food 
Meats, egg and sausage 
NEVER 
LESS THAN 
ONCE A 
MONTH 
TIMES A 
MONTH 
TIMES A WEEK TIMES A DAY 
Observations 
(01) (02) 
1-3 
(03) 
1 
(04) 
2-4 
(05) 
5-6 
(06) 
1 
(07) 
2-3 
(08) 
4-5 
(09) 
6 
(10) 
28  A chicken egg [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
29  A piece of chicken [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
30  A slice of ham [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
31  A plate of beef meat [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
32 A plate of pork meat (carnitas) [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
33  A portion of tuna fish [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
34  A piece of pork skin (dry) [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
35  A sausage or frank [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
36  A slice of bacon [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
37  A liver steak or chicken livers [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
38  A piece of sausage or chorizo [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
39  A plate of fresh fish (i.e. perch) [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
40  A plate of sardines in tomato [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
41  Half cup of seafood [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
42  Plate of shredded pork meat [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
43  A plate of Shredded beet meat-
BBQ 
[___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
44 A plate of Cooked Lamb [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
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During the year prior to this day, how often do you consume VEGETABLES? Please indicate with a cross in the column of frequencies, 
consider the option that is closest to reality. 
FREQUENCY OF CONSUMPTION 
Food 
Vegetables 
NEVER 
LESS 
THAN 
ONCE A 
MONTH 
TIMES 
A 
MONTH 
TIMES A WEEK TIMES A DAY 
METHOD OF COOKING 
Observa-
tions 
CRUDO 
EN 
AGUA 
EN 
ACEITE 
ASADO 
(01) (02) 
1-3 
(03) 
1 
(04) 
2-4 
(05) 
5-6 
(06) 
1 
(07) 
2-3 
(08) 
4-5 
(09) 
6 
(10) (A) (B) (C) (D) 
45 A tomato in sauce or stew [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
46 A raw tomato or in a salad [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
47 A potato  [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
48 A Sweet Potato [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
49 Half a cup of carrot [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
50 A cup of lettuce [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
51 Half cup of spinach or other leafy 
green vegetables 
[___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] 
 
52 Half cup of squash or chayote 
squash 
[___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] 
 
53 Half cup of cactus [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
54 Canned hot green chili peppers [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
55 Dry hot chili pepper dish [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
56 A plate of cream vegetable soup [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
57 Half of a avocado [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
58 Half a cup of pumpkin 
flower/zucchini blossoms 
[___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] 
 
59 Half a cup of cauliflower [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
60 Half a cup of green beans [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
61 A teaspoon of hot sauce or 
peppers with your food 
[___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] 
 
62 A dish with dried chili [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
63 An ear of corn [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
64 Half a cup of zucchini [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
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During the year prior to this day, how often do you consume CEREALS OR LEGUMES? Please indicate with a cross in the column of frequencies, 
consider the option that is closest to reality.  
FREQUENCY OF CONSUMPTION 
Food 
Legumes 
NEVER 
LESS 
THAN 
ONCE A 
MONTH 
TIMES A 
MONTH 
TIMES A WEEK TIMES A DAY Observations 
(01) (02) 
1-3 
(03) 
1 
(04) 
2-4 
(05) 
5-6 
(06) 
1 
(07) 
2-3 
(08) 
4-5 
(09) 
6 
(10) 
 
65 Un plato de frijoles [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
66 Media taza de chicharos [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
67 Un plato de habas verdes [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
68 Un plato de habas secas [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
69 Un plato de lentejas o garbanzos [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
FREQUENCY OF CONSUMPTION 
ALIMENTO 
Cereals 
NEVER 
LESS 
THAN 
ONCE A 
MONTH 
TIMES A 
MONTH 
TIMES A WEEK TIMES A DAY Observations 
(01) (02) 
1-3 
(03) 
1 
(04) 
2-4 
(05) 
5-6 
(06) 
1 
(07) 
2-3 
(08) 
4-5 
(09) 
6 
(10) 
 
70 64. A corn tortilla  [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
71 65. A flour tortilla [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
72 66. A slice of boxed white bread [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
73 67. A slice of boxed whole bread [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
74 68. A dinner or Kaiser roll [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
75 69. A piece of sweet bread [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
76 70. A plate of rice [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
77 71. A plate of pasta soup [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
78 72. A plate of oat [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
79 73. A bowl of cereal box (type of 
corn flakes). What 
kind?_________ 
[___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
80 74. High-fiber cereal. 
Which?_______ 
[___] [___] [___] [___] [___] [___] [___] [___] [___] [___] 
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During the year prior to this day, how often do you consume JUNK FOOD or DESSERT? Please indicate with a cross in the column of frequencies, 
consider the option that is closest to reality.  
FREQUENCY OF CONSUMPTION 
Food 
Junk food or dessert 
NEVER 
LESS THAN 
ONCE A 
MONTH 
TIMES 
A 
MONTH 
TIMES A WEEK TIMES A DAY 
Observations 
(01) (02) 
1-3 
(03) 
1 
(04) 
2-4 
(05) 
5-6 
(06) 
1 
(07) 
2-3 
(08) 
4-5 
(09) 
6 
(10) 
 
81  A piece of cake [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
82 A piece of Pastry (pie, donut, etc.) [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
83  A teaspoon of honey, jam, sweet-
condensed milk or caramel? 
[___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
84 A teaspoon of chocolate powder [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
85  A chocolate tablet/bar [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
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During the year prior to this day, how often do you consumed the fallowing BEVERAGES? Please indicate with a cross in the column of 
frequencies, consider the option that is closest to reality.  
FREQUENCY OF CONSUMPTION 
Food 
Beverages 
NEVER 
LESS THAN 
ONCE A 
MONTH 
TIMES A 
MONTH 
TIMES A WEEK TIMES A DAY Observations 
(01) (02) 
1-3 
(03) 
1 
(04) 
2-4 
(05) 
5-6 
(06) 
1 
(07) 
2-3 
(08) 
4-5 
(09) 
6 
(10) 
 
87 A medium size (can) cola drink [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
88  A flavored drink that has gas [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
89  A diet drink [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
90  A glass of sugared water [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
91 A cup of coffee without sugar [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
92 A up of Instant coffee [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
93 A cup of “atole” without milk [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
94 A cup of “atole” with milk [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
95 A beer [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
96 A cup of table wine [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
97 A drink with rum, brandy or tequila [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
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During the year prior to this day, how often do you consume FAT and what type of OIL do you use for cooking? Please indicate with a cross in the 
column of frequencies, consider the option that is closest to reality.  
FRECUENCIA DE CONSUMO 
ALIMENTO 
Oils and fats 
NEVER 
LESS THAN 
ONCE A 
MONTH 
TIMES A 
MONTH 
TIMES A WEEK TIMES A DAY Observations 
(01) (02) 
1-3 
(03) 
1 
(04) 
2-4 
(05) 
5-6 
(06) 
1 
(07) 
2-3 
(08) 
4-5 
(09) 
6 
(10) 
 
98 Corn oil [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
99  Soy oil [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
100 Sunflower oil [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
101 Safflower oil [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
102 Olive oil [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
103 A teaspoon of margarine [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
104 A teaspoon of butter [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
105 A teaspoon of sour cream [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
106 A teaspoon of mayonnaise [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
107 A teaspoon of vegetable 
shortening 
[___] [___] [___] [___] [___] [___] [___] [___] [___] [___] 
 
108 A teaspoon of animal fat [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
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During the year prior to this day, how often do you consume MEXICAN CRAVINGS? Please indicate with a cross in the column of frequencies, 
consider the option that is closest to reality.  
FREQUENCY OF CONSUMPTION 
Food 
Cravings 
NEVER 
LESS THAN 
ONCE A 
MONTH 
TIMES A 
MONTH 
TIMES A WEEK TIMES A DAY Observations 
(01) (02) 
1-3 
(03) 
1 
(04) 
2-4 
(05) 
5-6 
(06) 
1 
(07) 
2-3 
(08) 
4-5 
(09) 
6 
(10) 
 
109 A taco of pork [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
110 A sope or quesadilla [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
111 A plate of pozole [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
112  A tamal [___] [___] [___] [___] [___] [___] [___] [___] [___] [___]  
 
 
 
 
Please indicate any other food that you consumed at least once a week and that you did not find in the previously foods above, apart from the 
list below, the year prior to this day. Please indicate with a cross in the column of frequencies, consider the option that is closest to reality. 
FREQUENCY OF CONSUMPTION 
Food 
Other foods not listed 
TIMES A WEEK TIMES A DAY Observations 
1 
(04) 
2-4 
(05) 
5-6 
(06) 
1 
(07) 
2-3 
(08) 
4-5 
(09) 
6 
(10) 
 
  [___] [___] [___] [___] [___] [___] [___]  
  [___] [___] [___] [___] [___] [___] [___]  
  [___] [___] [___] [___] [___] [___] [___]  
  [___] [___] [___] [___] [___] [___] [___]  
  [___] [___] [___] [___] [___] [___] [___]  
  [___] [___] [___] [___] [___] [___] [___]  
  [___] [___] [___] [___] [___] [___] [___]  
  [___] [___] [___] [___] [___] [___] [___]  
  [___] [___] [___] [___] [___] [___] [___]  
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OTHER QUESTIONS 
 Observations 
 How many teaspoons of sugar you add to your food, or during the day? Consider what you put 
on coffee, milk shakes, other drinks, etc. 
Teaspoon  
 Do you add salt to your food before testing it? c) Yes d) No  
 Do you eat the skin of the chicken? c) Yes d) No  
 Do you eat the “fat” of the meat? c) Yes d) No  
 How many months last year did you consume vitamins? 
Which?___________________ 0 1-2 3-4 5-6 7-8 9-10 11-12 
 
  a b c d e f g  
  
  0 1-2 3-4 5-6 7-8 9-10 11-12  
 How many months last year did you consume a calcium supplement?  a b c d e f g  
 Which? ________________________________________________________________________________ 
 Do you consider that you have changed your eating habits during the last year?  c) Yes d) No  
 If they have changed, why? 
__________________________________________________________________________________________________________
__________________________________________________________________________________________________________ 
__________________________________________________________________________________________________________ 
 Observaions 
___________________________________________________________________________________________________________________ 
___________________________________________________________________________________________________________________ 
___________________________________________________________________________________________________________________ 
This is the end of the questionnaire, thank you for your participation. 
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Appendix H: Blood collection and processing protocol 
 
Standard Operating Procedure 
 
Preparing fresh serum for measurement of Beta-carotene 
NOTE: LIGHT SENSITIVE! This procedure should be completed in minimal light 
or under approved yellow lighting. 
 
Materials: 
 Light proof container with lid 
 Ice 
 Blood sample collected in a non-heparinized tube (red cap) 
 1.5 – 2 mL amber tubes with lid/cap 
 Foil 
 
 
 
Procedure: 
1. Once blood is collected it should be placed on ice in a covered light safe container. 
NOTE: The tube should rest ON TOP of the ice, NOT be submerged in the ice. 
 
2. Allow the blood to clot for 20-30 minutes, the serum and clot will separate. After 20 
minutes submerge the tube in the ice while preparing for the next steps. 
NOTE: The tube should be SUBMERGED in the ice AFTER the clot is formed. 
 
3. Centrifuge the tube for 20 minutes at 3000 rpm in a clinical centrifuge. 
NOTE: If serum gels, centrifuge again for 10 minutes this should liquefy it. 
 
 
4. In a dimly lit room, away from direct light, immediately separate the serum into 1 mL 
aliquots using a pipette. Deposit the serum into amber colored tubes. For added 
protection, cover the tubes in foil. 
 
5. Store the tubes at -80 °C until analysis. 
 
 
NOTE:  Serum should be separated from clot immediately after collection to ensure reliability of 
measurement. 
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Appendix I: Model list for covariates in correlations 
 
Model 
Number 
Covariates adjusted for in model 
Model 1 Sex, Age, Total calorie intake 
Model 2 Sex, Age, Total calorie intake, Total Cholesterol, Triglycerides 
Model 3 Sex, Age, Total calorie intake, High-Density Lipoprotein, Triglycerides 
Model 4 Sex, Age, Total calorie intake, Non-High-Density Lipoprotein, Triglycerides 
Model 3 Sex, Age, Percent of calories from fat 
Model 4 Sex, Age, Percent of calories from fat, Total Cholesterol, Triglycerides 
Model 5 Sex, Age, Percent of calories from fat, High-Density Lipoprotein, Triglycerides 
Model 6 Sex, Age, Percent of calories from fat, Non-High-Density Lipoprotein, 
Triglycerides 
Model 7 Sex, Age, Total calorie intake, Percent of calories from fat 
Model 8 Sex, Age, BMI, Total calorie intake, Total Cholesterol, Triglycerides (Romeiu, et al) 
Model 9 Sex, Age, BMI, Percent of calories from fat, Total Cholesterol, Triglycerides 
 
 
 
